

CITATION REPORT

List of articles citing

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

DOI: 10.1016/0065-2571(84)90007-4
Advances in Enzyme Regulation, 1984, 22, 27-55.

Source: <https://exaly.com/paper-pdf/17113411/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2236	Inhibiting Mycobacterium tuberculosis DosRST Signaling by Targeting Response Regulator DNA Binding and Sensor Kinase Heme.		
2235	Predictive Gene Signature for Pyrazolopyrimidine Derivative cSrc Inhibitor 10a Sensitivity in Melanoma Cells.		
2234	The proliferative response of low-density human cell cultures to tumor promoters and its relevance to carcinogenic mechanisms in vitro. 1984 , 34, 781-8		4
2233	The expected effect of a combination of agents: the general solution. 1985 , 114, 413-31		433
2232	Combined action of carbaryl and phenthoate on a freshwater fish (Channa punctatus bloch). 1985 , 10, 209-17		7
2231	Mode of inhibitory action of melittin on Na ⁺ -K ⁺ -ATPase activity of the rat synaptic membrane. 1985 , 34, 2335-41		14
2230	Antiviral drugs for AIDS. Current status and future prospects. 1986 , 31, 463-6		9
2229	Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid. 1986 , 37, 101-7		17
2228	Predictive models for potentiation of cell killing by combined exposure in vitro to photon radiation and BCNU. 1986 , 7, 1339-1352		1
2227	Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture. 1986 , 4, 315-23		3
2226	Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo. 1986 , 18, 1-4		28
2225	Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. 1986 , 30, 491-8		43
2224	Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. 1986 , 30, 189-91		61
2223	Ribavirin antagonizes the effect of azidothymidine on HIV replication. 1987 , 235, 1376-9		256
2222	Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil. 1987 , 31, 1355-8		36
2221	Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and recombinant human beta interferon alone and in combination on simian varicella virus infection in monkeys. 1987 , 156, 607-14		20
2220	Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date. 1987 , 34, 372-90		15

2219	Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. 1987 , 31, 168-72	218
2218	A statistical test for synergism of two cell growth inhibitors. 1987 , 46, 237-45	1
2217	Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cells. 1987 , 11, 1031-9	2
2216	Median effect and long term recovery analysis of biological modifier interactions with difluoromethylornithine on the proliferation of human melanoma cells. 1987 , 1, 124-8	3
2215	Chemosensitization by misonidazole in CCNU-treated spheroids and tumours. 1987 , 56, 103-9	7
2214	Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. 1988 , 42, 382-8	113
2213	Potentialiation of platinum analogue cytotoxicity by hyperthermia. 1988 , 21, 191-6	28
2212	The combined effects of mixtures of ionizing radiations. 1988 , 134, 531-46	11
2211	Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. 1988 , 58, 330-4	19
2210	Antagonistic interactions of hexamethylene bisacetamide in combination with 1-beta-D-arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro. 1988 , 12, 853-9	3
2209	Comparative quantitative electrophysiologic effects of adenosine triphosphate on the sinus node and atrioventricular node. 1988 , 61, 330-5	28
2208	Differential modulation of host cell and HIV gene expression by combinations of avarol and AZT in vitro. 1988 , 37, 3947-52	17
2207	Genetic influences on agonist binding to cardiac beta-receptors. 1988 , 37, 1281-6	3
2206	A Straightforward Method for the Study of Drug Interactions: An Isobolographic Analysis Primer. 1988 , 7, 987-1012	57
2205	Differential sensitivity of histone acetylation in nitrogen-mustard sensitive and resistant cells. Relation to drug uptake, formation and repair of DNA-interstrand cross-links. 1988 , 24, 1861-8	3
2204	Cellular pharmacology of N,N',N''-triethylene thiophosphoramidate. 1988 , 41, 157-68	14
2203	Isobolographic, Algebraic, and Search Methods in the Analysis of Multiagent Synergy. 1988 , 7, 927-938	19
2202	Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1. 1988 , 158, 378-85	44

2201	Synergism of thrombolytic agents: investigational procedures and clinical potential. 1988 , 77, 731-5	25
2200	Qualitative Evaluation of Sister Chromatid Exchanges Elicited by Combinations of Genotoxic Compounds Using Response Surface Methodology. 1988 , 7, 975-986	
2199	The rat hippocampal slice preparation as an in vitro model of ischemia. 1988 , 19, 498-502	59
2198	The Nature of Synergy between Tissue-Type and Single Chain Urokinase-Type Plasminogen Activators. 1989 , 62, 909-916	9
2197	Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. 1989 , 33, 778-80	59
2196	Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3'-azido-3'-deoxythymidine. 1989 , 33, 53-7	67
2195	Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine. 1989 , 33, 1482-6	30
2194	Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. 1989 , 33, 1975-9	31
2193	Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1. 1989 , 33, 2083-8	51
2192	In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. 1989 , 5, 193-203	25
2191	Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. 1989 , 33, 663-9	89
2190	Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases. 1989 , 33, 115-7	35
2189	Synergistic inhibition of Epstein-Barr virus: transformation of B lymphocytes by alpha and gamma interferon and by 3'-azido-3'-deoxythymidine. 1989 , 159, 248-54	21
2188	Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine. 1989 , 159, 837-44	57
2187	Analysis of interaction for mixtures of agents using the linear isobole. 1989 , 51, 293-309	9
2186	Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. 1989 , 24, 312-7	42
2185	Combined effects of interferon and steroid hormones on 2',5'-oligoadenylate synthetase activity in chronic lymphocytic leukemia cells. 1989 , 13, 437-43	5
2184	Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model. 1989 , 44, 911-7	16

2183	In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging. 1989 , 23, 129-34	6
2182	Inhibition of cell growth and macromolecule biosynthesis of human promyelocytic leukemic cells by acridone alkaloids. 1989 , 3, 237-242	30
2181	Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562. 1989 , 59, 347-8	29
2180	The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase. <i>Advances in Enzyme Regulation</i> , 1989 , 28, 13-21	2
2179	The phospholipid- and calcium-dependent protein kinase as a target in tumor chemotherapy. <i>Advances in Enzyme Regulation</i> , 1989 , 28, 201-16	21
2178	Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-CEM cell lines sensitive and resistant to methotrexate. <i>Advances in Enzyme Regulation</i> , 1989 , 28, 323-33	5
2177	Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. 1989 , 86, 3842-6	54
2176	Development of intestinal host defense: an increased sensitivity in the adenylate cyclase response to cholera toxin in suckling rats. 1989 , 25, 225-7	29
2175	Cisplatin and CCNU synergism in spheroid cell subpopulations. 1990 , 62, 947-53	16
2174	Potentialiation of cisplatin cytotoxicity by methylxanthines in vitro. 1990 , 116, 431-3	16
2173	Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture. 1990 , 26, 323-9	10
2172	Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase. 1990 , 26, 345-51	5
2171	Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro. 1990 , 9, 615-9	15
2170	Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer. 1990 , 10, 45-51	16
2169	Combination of flavone acetic acid (FAA) with adriamycin, cis-platinum and difluoromethylornithine (DFMO) in vitro against human colon cancer cells. 1990 , 8, 263-8	4
2168	Effects of 2'-deoxycyformycin on HL-60 cell differentiation, adenosine deaminase, and oligoadenylate synthetase. 1990 , 33, 274-6	1
2167	Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. 1990 , 161, 845-57	46
2166	Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. 1990 , 161, 1059-67	70

2165	On the use of the pion stopping distribution and the lesion additivity concept for the calculation of effective doses in pion treatment planning. 1990 , 35, 731-40	3
2164	On the biophysical interpretation of the mathematical product of dose and relative biological effectiveness. 1990 , 35, 481-8	2
2163	Synergistic inhibition of human immunodeficiency virus replication in vitro by combinations of 3'-azido-3'-deoxythymidine and 3'-fluoro-3'-deoxythymidine. 1990 , 6, 1197-202	30
2162	In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. 1990 , 34, 82-8	47
2161	Synergistic effects of vinblastine and recombinant interferon-beta on renal tumor cell lines. 1990 , 10, 281-91	4
2160	Combined effects of interferon and 2'-deoxycoformycin on 2',5'-oligoadenylate synthetase and adenosine deaminase in hairy cell and chronic lymphocytic leukemia cells. 1990 , 10, 535-40	1
2159	Antiviral Activity of Mixtures of Compounds against Herpesviruses. 1990 , 1, 125-129	
2158	Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. 1990 , 87, 3185-9	98
2157	Antiviral therapy against HIV infection. 1990 , 22, 1282-94	6
2156	Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. 1990 , 26, 724-7	31
2155	New developments in combination chemotherapy of anti-human immunodeficiency virus drugs. 1990 , 616, 318-27	4
2154	Synergistic drug combinations in AIDS therapy. Dipyridamole/3'-azido-3'-deoxythymidine in particular and principles of analysis in general. 1990 , 616, 367-84	27
2153	COMBO: A New Approach to the Analysis of Drug Combinations in Vitroa. 1990 , 616, 490-494	15
2152	Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. 1990 , 38, 155-60	44
2151	Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. 1990 , 38, 315-22	26
2150	Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. 1990 , 28, 293-8	67
2149	Statistical modeling of the effects of drug combinations. 1990 , 23, 297-309	28
2148	Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives. 1990 , 40, 1779-83	6

2147	Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate esters of 3'-azido-3'-deoxythymidine. 1990 , 172, 288-94	16
2146	A three-dimensional model to analyze drug-drug interactions. 1990 , 14, 181-205	496
2145	Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro. 1990 , 14, 249-65	9
2144	Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-beta. 1990 , 13, 165-74	15
2143	Evaluation of synergism or antagonism for the combined action of antiviral agents. 1990 , 13, 23-39	85
2142	Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime. <i>Advances in Enzyme Regulation</i> , 1991 , 31, 71-83	28
2141	Synergistic combinations and peptides in the inhibition of human immunodeficiency virus. <i>Advances in Enzyme Regulation</i> , 1991 , 31, 85-97	3
2140	Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferon. 1991 , 15, 323-30	13
2139	Inhibition of proliferation of human immunodeficiency virus type 1 by novel heteropolyoxotungstates in vitro. 1991 , 15, 113-24	55
2138	Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay. 1991 , 165, 245-55	18
2137	Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. 1991 , 41, 1283-92	96
2136	Biochemical and biological properties of methotrexate analogs containing D-glutamic acid or D-erythro, threo-4-fluoroglutamic acid. 1991 , 42, 2400-3	11
2135	The effects of Provera on chemotherapy of uterine cancer cell lines. 1991 , 42, 165-77	11
2134	Comparative evaluation of single and combination chemotherapy in uterine cancer cell lines. 1991 , 42, 227-32	15
2133	Synergy between preactivated photofrin-II and tamoxifen in killing retrofibroma, pseudomyxoma and breast cancer cells. 1991 , 27, 1034-9	11
2132	Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. 1991 , 88, 8806-10	234
2131	Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. 1991 , 88, 9959-63	142
2130	Antiproliferative effects of natural human tumor necrosis factor-alpha, interferon-alpha, and interferon-gamma on human pancreatic carcinoma cell lines. 1991 , 8, 235-43	15

2129	Modulation of vinblastine sensitivity by dipyrindamole in multidrug resistant fibrosarcoma cells lacking <i>mdr1</i> expression. 1991 , 64, 705-9	10
2128	B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance. 1991 , 47, 870-4	27
2127	Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part III--Combination experiments. 1991 , 324, 153-60	
2126	Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells. 1991 , 28, 370-6	7
2125	Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs. 1991 , 29, 133-40	2
2124	Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine. 1991 , 35, 2003-11	40
2123	Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon. 1991 , 35, 62-7	50
2122	Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. 1991 , 164, 646-55	122
2121	Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity. 1991 , 7, 975-81	13
2120	Neonatal red blood cells as a model for the study of ouabain-furosemide interaction on active K ⁺ transport. A theoretical approach. 1991 , 99, 281-5	1
2119	Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. 1991 , 35, 1060-5	80
2118	Anti-HIV Activities of Novel Nucleoside Analogues: Acyclic and Tricyclic Base Nucleosides. 1991 , 2, 329-336	3
2117	Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. 1991 , 35, 322-8	76
2116	Differential alteration of the anti-HIV-1 effect of phosphorothioate oligonucleotide S-dC28 by AZT, interferon-alpha, and dextran sulfate. 1991 , 7, 943-51	9
2115	BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. 1991 , 35, 305-8	159
2114	Inhibition of Human Immunodeficiency Virus Type 1 Replication by Guanosine Analogues and Lack of Synergistic Antiviral Effect of Acyclovir with 3'-azido-3'-deoxythymidine. 1991 , 2, 29-34	8
2113	Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro. 1991 , 35, 1430-3	21
2112	Synergistic Inhibition of Human Immunodeficiency Virus Type 1 in vitro by Interferon Alpha and Coumermycin A1. 1992 , 3, 183-188	5

2111	Diagnosis of vertical human immunodeficiency virus type 1 infection by whole blood culture. 1992 , 166, 1146-8	17
2110	Synergistic interaction of interferon-beta and interferon-gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. 1992 , 166, 958-65	55
2109	1-(Ethoxymethyl)-6-(Phenylselenenyl)Pyrimidines with Activity against Human Immunodeficiency Virus Types 1 and 2. 1992 , 3, 263-266	20
2108	Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. 1992 , 84, 1033-8	32
2107	Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. 1992 , 36, 2715-21	34
2106	Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. 1992 , 36, 920-5	45
2105	Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. 1992 , 36, 1559-62	62
2104	Amino- and Hydroxytetraphenylporphyrins with Activity against the Human Immunodeficiency Virus. 1992 , 3, 279-282	21
2103	Structure-activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1. 1992 , 36, 108-14	17
2102	Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. 1992 , 166, 1143-6	67
2101	Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. 1992 , 8, 425-7	51
2100	Development of antiviral treatment strategies in murine models. 1992 , 8, 997-1011	10
2099	Insights into HIV chemotherapy. 1992 , 8, 963-90	103
2098	Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells. 1992 , 41, 890-5	118
2097	Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro. 1992 , 36, 1127-30	31
2096	Analysis and examination of cytokine interactions by the median-effect model: an example with antiviral action of tumor necrosis factor and interferon-gamma. 1992 , 12, 161-5	5
2095	Three-drug synergistic inhibition of HIV-1 replication in vitro by 3'-fluoro-3'-deoxythymidine, recombinant soluble CD4, and recombinant interferon-alpha. 1992 , 8, 589-95	11
2094	Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. 1992 , 36, 672-6	261

2093	Anti-proliferative effect on human pancreatic cancer cells of natural human tumour necrosis factor-beta combined with natural human interferon-alpha or interferon-gamma. 1992 , 20, 112-20	6
2092	The effects of ICRF-154 in combination with other anticancer agents in vitro. 1992 , 66, 281-6	12
2091	Effects of folinic acid on 5-fluorouracil induced cell lethality with or without cisplatin against head and neck laryngeal squamous carcinoma multicellular tumor spheroids. 1992 , 112, 566-73	2
2090	Biochemical effects of piceatannol in human HL-60 promyelocytic leukemia cells - synergism with Ara-C. 1992 , 33, 887	2
2089	5?-Hydrogenphosphonates and 5?-Methylphosphonates of Sugar Modified Pyrimidine Nucleosides as Potential Anti-HIV-1 Agents.1. 1992 , 11, 177-196	27
2088	Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. 1992 , 8, 461-7	97
2087	The effect of combinations of amplitgen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro. 1992 , 17, 169-77	22
2086	Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro. 1992 , 47, 172-8	8
2085	Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay. 1992 , 47, 186-90	9
2084	Determination of hormonal response in uterine cancer cell lines by the ATP bioluminescence assay and flow cytometry. 1992 , 46, 55-61	12
2083	Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell lines. 1992 , 45, 164-73	6
2082	The use of ATP bioluminescence assays in selecting a drug screen panel for chemosensitivity testing of uterine cancer cell lines. 1992 , 45, 185-91	5
2081	Anti-viral activity of human recombinant heparin-binding proteins HBNF and MK. 1992 , 189, 1189-95	4
2080	Active-site directed irreversible inhibition of diamine oxidase by a homologous series of aziridinyalkylamines. 1992 , 44, 1229-32	4
2079	In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. 1992 , 29, 430-4	20
2078	Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro. 1992 , 30, 286-90	16
2077	Regulatory and antiproliferative effects of N-alkylated polyamine analogues in human and hamster pancreatic adenocarcinoma cell lines. 1992 , 30, 183-8	32
2076	Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin. 1992 , 30, 31-6	18

2075	In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines. 1992 , 30, 37-42	8
2074	Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. 1992 , 83, 532-9	10
2073	Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas. 1992 , 10, 182-9	5
2072	Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity. 1992 , 118, 515-22	6
2071	The study of combined action of agents using differential geometry of dose-effect surfaces. 1992 , 54, 813-26	1
2070	Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. 1992 , 191, 732-42	90
2069	New immunosuppressive drugs: needs in and applications to pediatric transplantation. 1992 , 151 Suppl 1, S9-12	4
2068	Trichothecene synergism, additivity, and antagonism: the significance of the maximally quiescent ratio. 1992 , 1, 38-47	28
2067	Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation. 1993 , 72, 1914-8	25
2066	Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. 1993 , 55, 1018-22	30
2065	Synthesis and antitumor activity of ammine/amine platinum(II) and (IV) complexes. 1993 , 51, 677-87	53
2064	Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro. 1993 , 23, 25-36	12
2063	Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. 1993 , 32, 339-46	11
2062	Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay. 1993 , 28, 21-7	19
2061	Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. 1993 , 31, 259-64	49
2060	Analysis of the cytotoxic interaction between cisplatin and hyperthermia in a human ovarian carcinoma cell line. 1993 , 32, 419-24	12
2059	Selective modulation of vinblastine sensitivity by 1,9-dideoxyforskolin and related diterpenes in multidrug resistant tumour cells. 1993 , 67, 471-9	2
2058	Fluoropyrimidines as radiation sensitizers. 1993 , 3, 20-28	32

2057	A structure-activity relationship study of batracylin analogues. 1993 , 10, 918-23	19
2056	Synthesis and testing of new antileukemic Schiff bases of N-hydroxy-N'-aminoguanidine against CCRF-CEM/0 human leukemia cells in vitro and synergism studies with cytarabine (Ara-C). 1993 , 10, 515-20	14
2055	Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. 1993 , 119, 727-33	83
2054	The differential aspects of the linear isobole in the study of combined action of agents. 1993 , 55, 295-313	3
2053	Competitive inhibitors of human immunodeficiency virus reverse transcriptase. 1993 , 1, 151-180	44
2052	Prätherapeutische in-vitro-Chemosensitivität bei gynäkologischen Tumoren. Einsatz des ATP-CSA (ATP-Chemo-Sensitivitäts-Assay). 1993 , 254, 1074-1076	
2051	Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro. 1993 , 45, 2079-85	30
2050	Synergistic antiproliferative effects of interleukin-1 alpha and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3). 1993 , 45, 2099-107	7
2049	Polyamine and pentamidine metabolism in African trypanosomes. 1993 , 54, 215-24	24
2048	Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection. 1993 , 21, 327-42	22
2047	In vitro evaluation of experimental agents for anti-HIV activity. 2001 , Chapter 12, Unit 12.9	9
2046	Synergistic interactions of etoposide and interleukin-1 alpha are not due to DNA damage in human melanoma cells. 1993 , 1180, 231-5	6
2045	Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. 1993 , 33, 245-50	14
2044	Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole. 1993 , 33, 163-70	10
2043	Effects of mitomycin-C and etoposide in cell culture and in nude mice: the role of G-CSF mutein. 1993 , 11, 283-90	0
2042	A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. 1993 , 9, 985-96	33
2041	Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. 1993 , 37, 875-81	349
2040	Synergistic interaction of natural human tumor necrosis factor-alpha/natural human interferon-alpha mixture alone and in combination with cisplatin against head and neck laryngeal squamous carcinoma multicellular tumor spheroids. 1993 , 20, 53-62	1

2039	Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates. 1993 , 41, 297-310	11
2038	Diagnosis and quantitation of HIV-1 infection in infants and children by whole-blood culture. 1993 , 693, 258-61	2
2037	The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions. 1993 , 37, 523-31	41
2036	Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1. 1993 , 37, 144-7	10
2035	Antiviral Synergy between Inhibitors of HIV Proteinase and Reverse Transcriptase. 1993 , 4, 161-166	24
2034	Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication. 1993 , 90, 3953-7	48
2033	Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine. 1993 , 168, 318-26	19
2032	Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. 1993 , 9, 581-7	35
2031	In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines. 1993 , 11, 276-82	12
2030	Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. 1993 , 37, 2206-11	39
2029	2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (1110U81) potently inhibits human cytomegalovirus replication and potentiates the antiviral effects of ganciclovir. 1993 , 37, 602-4	10
2028	Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993 , 37, 1095-101	272
2027	Evaluation of the combination effect of different antiviral compounds against HIV in vitro. 1993 , 25, 365-71	19
2026	Myelotoxicity of rifabutin and 3'-azido-3'-deoxythymidine, alone and in combination, to human hematopoietic progenitor cells in vitro. 1993 , 61, 77-82	5
2025	ATP-Cell Viability Assay Methodology in Both Fresh Gynecologic Tumors and Cell Lines. 1994 , 19, 108-121	4
2024	Combination therapy for infection due to human immunodeficiency virus type 1. 1994 , 18, 516-24	38
2023	Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. 1994 , 38, 348-52	15
2022	Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. 1994 , 38, 656-61	29

2021	Drug Combination of AZT and ddI: Synergism of Action and Prevention of Appearance of AZT-Resistance. 1994 , 5, 51-55	8
2020	SYNERGISM OF CYTOTOXICITY BETWEEN CIS-DIAMINEDICHLORO-PLATINUM-(II) AND CIS-DIAMINE(1,1-CYCLOBUTANEDICARBOXYLATE)-PLATINUM-(II). 1994 , 4, 329	
2019	Bisheteroaryl piperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. 1994 , 38, 288-93	56
2018	Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. 1994 , 38, 688-92	108
2017	Combination effect on HIV infection in vitro of soluble CD4 and HIV-neutralizing antibodies. 1994 , 134, 179-84	5
2016	Immunosuppressive therapy: Current limitations and future prospects. 1994 , 2, 31-48	1
2015	Signaling and drug sensitivity. 1994 , 13, 175-89	31
2014	Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. 1994 , 70, 449-52	33
2013	Modulation of adriamycin resistance in human breast carcinoma MCF-7 cells in vitro and in vivo by medroxyprogesterone acetate. 1994 , 85, 542-9	8
2012	Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line. 1994 , 34, 484-90	1
2011	Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I. 1994 , 47, 2105-10	20
2010	Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. 1994 , 47, 839-52	83
2009	Toxic responses to defined chemical mixtures: mathematical models and experimental designs. 1994 , 55, 635-51	9
2008	Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. 1994 , 24, 17-26	25
2007	Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. 1994 , 24, 275-88	91
2006	Efficacy of ganciclovir in combination with zidovudine against cytomegalovirus in vitro and in vivo. Freitas, V.R., Fraser-Smith, E.B., Chiu, S., Michelson, S. and Schatzman, R.C. (1993) Antiviral Res. 21, 301-315. 1994 , 24, 357-64	
2005	Multiple drug effect analysis with confidence interval. 1994 , 25, 1-11	70
2004	Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. 1994 , 1226, 89-96	19

2003	Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines. 1994 , 30A, 520-5	21
2002	Antileukemic activity studies and cellular pharmacology of the analogues of 2-hydroxy-1H-isoindole-1,3-dione (HISD) alone and in combination with cytosine arabinoside (ara-C) against human leukemia cells CEM/0. 1994 , 33, 953-61	4
2001	Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells. 1994 , 20, 625	12
2000	Contributions of flow cytometry to studies with multicell spheroids. 1994 , 42 Pt B, 405-22	4
1999	Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. 1994 , 69, 299-306	102
1998	Assessment of Synergistic and Antagonistic Effects of Chemotherapeutic Agents in vitro. 1994 , 19, 91-107	25
1997	Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. 1994 , 70, 409-14	20
1996	[The synergistic effect of delta-aminolevulinic acid and photodynamic laser therapy based on an in vitro model of the ATP tumor chemosensitivity test]. 1995 , 35, 85-9	5
1995	In-vitro synergism between t-PA and scu-PA depends on clot retraction. 1995 , 9, 101-105	5
1994	Effect of T-2 toxin and verrucarin A in combination on <i>Kluyveromyces marxianus</i> . 1995 , 3, 104-8	8
1993	Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand. 1995 , 25, 2882-7	36
1992	Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. 1995 , 61, 409-15	45
1991	Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. 1995 , 62, 283-90	29
1990	Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells. 1995 , 20, 315-23	7
1989	Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. 1996 , 37, 222-8	22
1988	Assessing sensitivity in suspension to cytosine arabinoside: statistical analysis, associations with clinical outcome and experimental design. 1995 , 14, 1081-95; discussion 1097	1
1987	The biological activity of cisplatin and dibromodulcitol in combination therapy. 1995 , 71, 317-21	2
1986	Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays. 1995 , 270, 31046-51	65

1985	In vitro Antimyxovirus and Anti-Human Immunodeficiency Virus Activities of Polyoxometalates. 1995 , 6, 114-122	39
1984	Phase-I and phase-ii trials of a laboratory-derived synergistic combination of Cisplatin and 2'-deoxy-5-azacytidine. 1995 , 6, 447-50	4
1983	Synergism between corticosteroids and Rapamycin for the treatment of intraocular inflammation. 1995 , 3, 195-202	4
1982	Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team. 1995 , 171, 297-304	13
1981	In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. 1995 , 171, 61-7	32
1980	Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. 1995 , 1270, 12-8	28
1979	Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. 1995 , 31A, 981-6	29
1978	Synergistic interaction of 3 M KCl-extracted donor antigens (e-HAg) with cyclosporine or cyclosporine/sirolimus for prolongation of rat heart allograft survival. 1995 , 3, 335-41	4
1977	Microcalorimetric evaluation of the effect of combined chemotherapeutic drugs. 1995 , 1244, 283-90	6
1976	Effects of Taxol on choriocarcinoma cells. 1995 , 173, 1835-42	14
1975	Effect of tamoxifen on mitoxantrone cytotoxicity in drug-sensitive and multidrug-resistant MCF-7 cells. 1995 , 36, 368-72	12
1974	Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin. 1995 , 35, 471-82	15
1973	Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity. 1995 , 35, 489-95	23
1972	Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines. 1995 , 35, 511-8	14
1971	Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines. 1995 , 35, 191-9	9
1970	Assessment of effect of photosensitizers on cytotoxicity of photodynamic therapy in human breast cancer cell cultures. 1995 , 256, 167-76	13
1969	Cultured human myocardial fibroblasts of pediatric origin: natural human interferon-alpha is more effective than recombinant interferon-alpha 2a in carrier-state coxsackievirus B3 replication. 1995 , 27, 2199-208	32
1968	Assessing the interaction of irradiation with etoposide or idarubicin. 1995 , 70, 1053-60	17

1967	Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells. 1995 , 88, 133-40	4
1966	Determination of HIV-1 susceptibility to reverse transcriptase (RT) inhibitors by a quantitative cell-free RT assay. 1996 , 7, 111-9	2
1965	Factors affecting topotecan sensitivity in human leukemia samples. 1996 , 803, 128-42	9
1964	Effects of benzophenanthridine alkaloids on the phosphorylation of an approximately 44 kDa protein present in a mitochondrial fraction of the rat heart. 1996 , 51, 151-7	11
1963	A checkerboard method to evaluate interactions between drugs. 1996 , 51, 635-44	53
1962	Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. 1996 , 52, 1855-65	488
1961	In vitro evaluation of Taxol combined with radiations in human squamous cell carcinoma spheroids. 1996 , 109, 23-32	13
1960	Intracellular metabolism of zidovudine and stavudine in combination. 1996 , 174, 671-2	20
1959	Synergistic interaction between dehydroepiandrosterone and prednisolone in the inhibition of rat lymphocyte proliferation. 1996 , 18, 443-56	9
1958	Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. 1996 , 40, 234-6	127
1957	Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. 1996 , 14, 3074-84	126
1956	Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. 1996 , 40, 1346-51	38
1955	Synergistic Inhibition of HIV-1 Reverse Transcriptase and HIV-1 Replication by Combining Troviridine with AZT, ddl and ddC in Vitro. 1996 , 7, 221-229	4
1954	Anti-HIV Activity of MDL 74968, a Novel Acyclonucleotide Derivative of Guanine: Drug Resistance and Drug Combination Effects in Vitro. 1996 , 7, 253-260	3
1953	Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153. 1996 , 73, 18-23	24
1952	Analysis of the interactions between an enzyme and multiple inhibitors using combination plots. 1996 , 320 (Pt 1), 17-26	15
1951	In vitro activity on myeloid progenitors of a combination of 2-chloro-2'-deoxyadenosine and interferon alpha: the effects of IL-1 and GM-CSF. 1996 , 20, 777-80	17
1950	The significance of the sequence of administration of topotecan and etoposide. 1996 , 39, 109-12	66

1949	Antitumor effects of human recombinant interleukin-1 alpha and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo. 1996 , 9, 199-208	3
1948	The three fates of immuno suppression in the next millenium: selectivity, synergy, and specificity. 1996 , 9, 527-534	
1947	Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo. 1996 , 68, 583-7	3
1946	Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. 1996 , 77, 76-85	19
1945	The three fates of immunosuppression in the next millenium: selectivity, synergy, and specificity. 1996 , 9, 527-34	4
1944	A complex interaction between topical verapamil and timolol on intraocular pressure in conscious rabbits. 1996 , 354, 198-204	5
1943	3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. 1996 , 74, 1030-6	96
1942	Combination toxicity of etoposide (VP-16) and photosensitisation with a water-soluble aluminium phthalocyanine in K562 human leukaemic cells. 1996 , 74, 1570-7	18
1941	Reply. 1996 , 174, 672-672	
1940	In vitro inhibition of the replication of human immunodeficiency virus type 1 by beta-mercaptoethylamine (cysteamine). 1996 , 174, 214-8	33
1939	Recombinant Interferons beta and gamma have a higher antiviral activity than interferon-alpha in coxsackievirus B3-infected carrier state cultures of human myocardial fibroblasts. 1996 , 16, 283-7	31
1938	Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. 1996 , 271, 10508-14	86
1937	The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers?. 1996 , 88, 699-700	63
1936	Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. 1996 , 84, 1024-32	54
1935	Synergistic Inhibition of Human Immunodeficiency Virus Type 1 Replication in Vitro by Two- and Three-Drug Combinations of Delavirdine, Lamivudine and Zidovudine. 1997 , 8, 333-341	3
1934	A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. 1997 , 175, 561-6	9
1933	Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. 1997 , 11, 1041-4	7
1932	Thiadiazole derivatives: highly potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replications in vitro. 1997 , 41, 301-8	9

1931	Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. 1997 , 52, 798-806	48
1930	Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. 1997 , 17, 681-93	33
1929	Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. 1997 , 37, 405-15	170
1928	Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. 1997 , 11, 469-75	11
1927	A General Synthetic Method of 5-Carboranyluracil Nucleosides with Potential Antiviral Activity and use in Neutron Capture Therapy. 1997 , 16, 2133-2150	9
1926	Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. 1997 , 13, 647-56	56
1925	Antiviral activity of meliacine on the replication of a thymidine kinase-deficient mutant of Herpes simplex virus type 1 alone and in combination with acyclovir. 1997 , 9, 49-55	18
1924	In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. 1997 , 33, 463-70	64
1923	Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. 1997 , 5, 225-32	187
1922	Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin. 1997 , 33, 122-8	11
1921	Sirolimus: a new agent for clinical renal transplantation. 1997 , 29, 48-50	72
1920	Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. 1997 , 13, 789-96	25
1919	Integrated approaches for the analysis of toxicologic interactions of chemical mixtures. 1997 , 27, 175-97	23
1918	Synergism between sirolimus and 1,25-dihydroxyvitamin D3 in vitro and in vivo. 1997 , 79, 138-47	41
1917	Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I. 1997 , 41, 977-81	17
1916	Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. 1997 , 41, 1058-63	124
1915	Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. 1997 , 41, 965-71	68
1914	In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. 1997 , 41, 2367-73	44

1913	Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides. 1997 , 41, 875-7	6
1912	Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. 1997 , 75, 1593-600	36
1911	Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. 1997 , 75, 333-40	26
1910	Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer. 1997 , 176, 759-66; discussion 766-8	24
1909	Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. 1997 , 34, 51-63	14
1908	Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha. 1997 , 34, 101-11	25
1907	The synergistic effect of bactobolamine and tacrolimus on in vitro and in vivo experiments. 1997 , 27, 1160-1166	
1906	A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity. 1997 , 25, 713-30	16
1905	Tamoxifen enhances interferon-regulated gene expression in breast cancer cells. 1997 , 167, 169-77	30
1904	Analogues of taurine as inhibitors of the phosphorylation of an 20K molecular weight protein present in a mitochondrial fraction of the rat retina. 1997 , 13, 115-130	7
1903	Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3. 1997 , 71, 311-9	21
1902	Activity of retinoic acid receptor-gamma selectively binding retinoids alone and in combination with interferon-gamma in breast cancer cell lines. 1997 , 71, 497-504	26
1901	Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. 1997 , 73, 729-34	62
1900	Emerging strategies for the clinical application of rapamycin. 1998 , 31, 341-4	11
1899	The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry. 1998 , 244, 530-41	23
1898	Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). 1998 , 56, 635-44	62
1897	Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. 1998 , 56, 1315-22	54
1896	Drug combinations: from laboratory to practice. 1998 , 132, 6-8	35

1895	Inhibition of 11beta-hydroxysteroid dehydrogenase by bioflavonoids and their interaction with furosemide and gossypol. 1998 , 132, 32-8	15
1894	Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors. 1998 , 38, 63-73	9
1893	1 Analysis of drug interactions. 1998 , 12, 153-168	6
1892	Parallel dose-response curves in combination experiments. 1998 , 60, 197-213	21
1891	Combination of cisplatin and radiation in cell culture: effect of duration of exposure to drug and timing of irradiation. 1998 , 75, 635-42	31
1890	Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis. 1998 , 78, 377-84	13
1889	Independent and joint action of cis- and trans-permethrin in <i>Triatoma infestans</i> (Hemiptera: Reduviidae). 1998 , 37, 225-230	13
1888	Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-arabinofuranosyl-2-fluoroadenine. 1998 , 124, 367-73	10
1887	Parameters Affecting Photodynamic Activity of Foscan or Meta-tetra(hydroxyphenyl)chlorin (mTHPC) In Vitro and In Vivo. 1998 , 13, 119-125	25
1886	Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells. 1998 , 129, 199-204	19
1885	Cytotoxicity and DNA binding characteristics of dextran-conjugated doxorubicins. 1998 , 1380, 329-35	15
1884	Anti-growth factor therapy for lung cancer. 1998 , 1, 377-88	7
1883	Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia. 1998 , 63, 545-52	14
1882	Synergistic action of tiazofurin and genistein on growth inhibition and differentiation of K-562 human leukemic cells. 1998 , 63, 1975-81	13
1881	Commentary: Some Critical Issues and Concerns Related to Research Advances on the Toxicology of Chemical Mixtures. 1998 , 106, 1059	18
1880	A Completely Diastereoselective Electrophilic Fluorination of a Chiral, Noncarbohydrate Sugar Ring Precursor: Application to the Synthesis of Several Novel 2-Fluoronucleosides. 1998 , 63, 2161-2167	67
1879	Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells. 1998 , 247, 759-64	9
1878	Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. 1998 , 55, 523-31	51

1877	Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells. 1998 , 55, 1353-60	15
1876	p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. 1998 , 188, 2033-45	704
1875	Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. 1998 , 90, 370-80	127
1874	c-Myc is a major mediator of the synergistic growth inhibitory effects of retinoic acid and interferon in breast cancer cells. 1998 , 273, 30608-13	25
1873	Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma. 1998 , 18, 209-14	25
1872	Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. 1998 , 95, 15798-802	149
1871	Editorial. 1998 , 11, 1-1	
1870	Unusual potentiation by vinca alkaloids of the cytostatic and cytotoxic action of methyl-3,5-diiodo-4-(4'-methoxyphenoxy) benzoate (DIME) and its nonhydrolyzable ethanone analog (DIPE) on MDA-MB-231 human mammary cancer cells. 1998 , 13, 49-55	
1869	Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. 1998 , 19, 135-44	8
1868	Reversal of anticancer multidrug resistance by the ardeemins. 1998 , 95, 8369-74	58
1867	Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. 1998 , 77, 1378-85	48
1866	Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro. 1998 , 77, 1737-43	14
1865	Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. 1998 , 95, 9642-7	195
1864	Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects. 1998 , 78, 11-22	44
1863	Synthesis and biological properties of the four optical isomers of 5-o-carboranyl-2',3'-didehydro-2',3'-dideoxyuridine. 1998 , 17, 711-27	8
1862	Analysis of the combined effect of two linear inhibitors on a single enzyme. 1998 , 329 (Pt 3), 689-98	37
1861	Pharmacological studies on the novel antiallergic drug HQL-79: I. Antiallergic and antiasthmatic effects in various experimental models. 1998 , 78, 1-10	22
1860	Some critical issues and concerns related to research advances on toxicology of chemical mixtures. 1998 , 106 Suppl 4, 1059-63	14

1859	Mechanism of action and in vitro activity of 1',3'-dioxolanylurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. 1999 , 43, 2376-82	73
1858	Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against <i>Toxoplasma gondii</i> . 1999 , 43, 758-62	11
1857	Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach. 1999 , 93, 1308-1318	174
1856	National cancer institute leases new supercomputer. 1999 , 91, 1191A-191	
1855	Photodynamic effects in vitro in fresh gynecologic tumors analyzed with a bioluminescence method. 1999 , 37, 115-20	4
1854	Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivative. 1999 , 10, 71-7	8
1853	Re: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. 1999 , 91, 285-6	1
1852	Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation. 1999 , 15, 861-7	5
1851	Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. 1999 , 10, 2679-87	22
1850	A model-based approach for assessing in vivo combination therapy interactions. 1999 , 96, 13023-8	18
1849	Enantioselective synthesis and biological evaluation of 5-o-carboranyl pyrimidine nucleosides. 1999 , 7, 2759-66	11
1848	The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. 1999 , 43, 607-16	65
1847	Physico-chemical and biological analysis of true combinatorial libraries. 1999 , 725, 17-37	11
1846	Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1. 1999 , 13, 1046-55	28
1845	Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. 1999 , 18, 2241-51	569
1844	Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. 1999 , 80, 981-90	158
1843	Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. 1999 , 44, 117-23	141
1842	Interactions among plant defense compounds: a method for analysis. 1999 , 9, 81-92	65

1841	The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir: part I. Synthesis and in vitro anti-hepatitis B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir. 1999 , 40, 167-78	30
1840	Potential of cytotoxicity and radiosensitization of (E)-2-deoxy-2'-(fluoromethylene) cytidine by pentoxifylline in vitro. 1999 , 80, 155-60	13
1839	Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations. 1999 , 35 Suppl 1, S3-8	24
1838	Synergistic anti-varicella-zoster virus activity of interferon-alpha 2a and acyclovir in corneal cells. 1999 , 289, 203-10	1
1837	Evaluation of anti-HSV-2 activities of <i>Barleria lupulina</i> and <i>Clinacanthus nutans</i> . 1999 , 67, 179-87	65
1836	FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. 1999 , 31, 1224-6	25
1835	Synergistic down-regulation of signal transduction and cytotoxicity by tiazofurin and quercetin in human ovarian carcinoma cells. 1999 , 64, 1869-76	26
1834	Amplification of signal transduction capacity and down-regulation by drugs. <i>Advances in Enzyme Regulation</i> , 1999 , 39, 51-66	10
1833	Tamoxifen radiosensitization in human glioblastoma cell lines. 1999 , 90, 533-6	15
1832	Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. 1999 , 13, 1273-4	32
1831	Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates. 1999 , 22, 430-6	10
1830	Interactions Among Combinations of Two and Three Protease Inhibitors Against Drug-Susceptible and Drug-Resistant HIV-1 Isolates. 1999 , 22, 430	9
1829	Resistance to paclitaxel induces time-delayed multinucleation and DNA fragmentation into large fragments in MCF-7 human breast adenocarcinoma cells. 2000 , 11, 295-302	12
1828	Toxicity and DNA binding of dextran-doxorubicin conjugates in multidrug-resistant KB-V1 cells: optimization of dextran size. 2000 , 11, 377-84	25
1827	Cytotoxicity of aphidicolin and its derivatives against neuroblastoma cells in vitro: synergism with doxorubicin and vincristine. 2000 , 11, 479-85	3
1826	Combined 4-hydroxy-ifosfamide and vinorelbine treatment in established and primary human breast cell cultures. 2000 , 11, 587-94	4
1825	Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin. 2000 , 63, 176-83	19
1824	Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents. 2000 , 35, 663-8	18

1823	Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. 2000 , 88, 977-85	53
1822	Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles. 2000 , 41, 62-72	19
1821	Evidence against potassium as an endothelium-derived hyperpolarizing factor in rat mesenteric small arteries. 2000 , 129, 605-11	49
1820	Rational design of biologically active peptides: inhibition of T cell activation through interference with CD4 function. <i>Transplant Int</i> (2000) 13 [Suppl 1]: S306-S310. 2000 , 13, 456-61	
1819	Rational design of biologically active peptides: inhibition of T cell activation through interference with CD4 function. 2000 , 13, S306-S310	1
1818	Tamoxifen and ATP synergistically activate Cl ⁻ release by cultured bovine pigmented ciliary epithelial cells. 2000 , 525 Pt 1, 183-93	14
1817	Anti-herpes simplex virus component isolated from <i>Maclura cochinchinensis</i> . 2000 , 6, 421-4	30
1816	The effects of Delta(12)-PGJ(2) on malignant cells. 2000 , 62, 75-90	6
1815	Basis for effective combination cancer chemotherapy with antimetabolites. 2000 , 87, 227-53	216
1814	Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line. 2000 , 85, 151-61	21
1813	Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1. 2000 , 46, 223-32	23
1812	Synergistic interactions of antibodies in rate of virus neutralization. 2000 , 270, 386-96	14
1811	Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution. 2000 , 164, 134-42	31
1810	Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. 2000 , 82, 1519-27	4
1809	Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. 2000 , 83, 1069-76	67
1808	Rational design of biologically active peptides: inhibition of T cell activation through interference with CD4 function. 2000 , 13 Suppl 1, S306-10	1
1807	Erratum: <i>Transplant Int</i> (2000) 13 [Suppl 1]: S306-S310. 2000 , 13, 456-461	
1806	Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. 2000 , 18, 1748-57	101

1805	BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. 2000 , 44, 2093-9	168
1804	Synergistic Inhibition of HIV-1 in Activated and Resting Peripheral Blood Mononuclear Cells, Monocyte-Derived Macrophages, and Selected Drug-Resistant Isolates With Nucleoside Analogues Combined With a Natural Product, Resveratrol. 2000 , 246-255	13
1803	Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study. 2000 , 12, 421-30	1
1802	Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. 2000 , 25, 246-55	69
1801	Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. 2000 , 18, 695-701	34
1800	Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. 2000 , 181, 484-90	84
1799	Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalineethylpyridylthioureas as potent antiviral agents. 2000 , 11, 141-55	6
1798	In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine. 2000 , 11, 213-9	8
1797	Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. 2000 , 44, 1328-32	88
1796	The relevance of drug sequence in combination chemotherapy. 2000 , 3, 335-356	35
1795	Down-regulation by drugs of the increased signal transduction in cancer cells. <i>Advances in Enzyme Regulation</i> , 2000 , 40, 19-34	5
1794	Combining iron chelators with the nucleoside analog didanosine in anti-HIV therapy. 2000 , 23, 249-50	5
1793	The chemotherapeutic agent bleomycin in a two-drug combination with zidovudine, ritonavir or indinavir synergistically inhibits HIV Type-1 replication in peripheral blood lymphocytes. 2001 , 18, 513-8	4
1792	Sirolimus: a comprehensive review. 2001 , 2, 1903-17	100
1791	Evaluating Chemical Interaction Studies for Mixture Risk Assessment. 2001 , 7, 259-306	39
1790	[Oxidative metabolism of HIV-infected macrophages: the role of glutathione and a pharmacologic approach]. 2001 , 49, 567-71	5
1789	Toxicology of simple and complex mixtures. 2001 , 22, 316-22	144
1788	Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. 2001 , 37, 402-13	111

1787	Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. 2001 , 72, 371-8; discussion 378-9	64
1786	CROSS-RESISTANCE AND COMBINED CYTOTOXIC EFFECTS OF PACLITAXEL AND CISPLATIN IN BLADDER CANCER CELLS. 2001 , 165, 2082-2085	12
1785	Signal Transduction Events Elicited by Natural Products that Function as Cancer Chemopreventive Agents. 2001 , 39, 83-107	8
1784	Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. 2001 , 60, 290-301	99
1783	Rapamycin: clinical results and future opportunities. 2001 , 72, 1181-93	185
1782	Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer. 2001 , 12, 595-602	3
1781	Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. 2001 , 12, 683-90	43
1780	Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. 2001 , 12, 741-51	30
1779	Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. 2001 , 97, 2105-14	25
1778	Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy. 2001 , 11, 365-71	4
1777	Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies. 2001 , 268, 2856-66	20
1776	In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. 2001 , 37, 69-82	58
1775	Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission?. 2001 , 30, 190-6	29
1774	Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. 2001 , 67, 223-33	25
1773	VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. 2001 , 68, 55-64	40
1772	Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells. 2001 , 84, 1571-6	63
1771	Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. 2001 , 69, 48-56	124
1770	Median effect analysis of efficacy versus adverse effects of immunosuppressants. 2001 , 70, 74-81	55

1769	Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. 2001 , 8, 662-8	42
1768	Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. 2001 , 15, 342-7	161
1767	Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes. 2001 , 15, 1852-9	21
1766	Synergistic effects of highly unsaturated fatty acid-containing phosphatidyl-ethanolamine on differentiation of human leukemia HL-60 cells by dibutyl cyclic adenosine monophosphate. 2001 , 92, 666-72	20
1765	Inhibition of the early phase of HIV replication by an isothiazolone, PD 161374. 2001 , 49, 101-14	23
1764	Lactoferrin and cyclic lactoferrin inhibit the entry of human cytomegalovirus into human fibroblasts. 2001 , 51, 141-9	148
1763	Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. 2001 , 51, 189-202	25
1762	Cytotoxic synergism of methioninase in combination with 5-fluorouracil and folinic acid. 2001 , 61, 867-76	20
1761	Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). 2001 , 61, 1497-507	14
1760	Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses. 2001 , 12, 161-7	6
1759	Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates. 2001 , 184, 1336-40	10
1758	Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. 2001 , 75, 12198-208	141
1757	Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. 2001 , 75, 7470-80	144
1756	Differential sensitization by orobol in proliferating and quiescent human ovarian carcinoma cells. 2001 , 18, 337-42	
1755	UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice. 2001 , 19, 193	
1754	Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. 2001 , 85, 1077-83	49
1753	Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. 2001 , 84, 579-85	38
1752	Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. 2001 , 276, 35194-200	102

1751	Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. 2001 , 98, 15221-6	161
1750	The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. 2001 , 98, 8113-8	107
1749	Docetaxel and herceptin: foundation for future strategies. 2001 , 6 Suppl 3, 22-5	10
1748	Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. 2001 , 183, 1121-5	106
1747	Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against <i>Toxoplasma gondii</i> . 2001 , 45, 48-51	18
1746	The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors. 2001 , 276, 44653-62	8
1745	Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. 2001 , 75, 9177-86	44
1744	A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. 2001 , 17, 1757-65	436
1743	Geraniol, a component of plant essential oils, sensitizes human colonic cancer cells to 5-Fluorouracil treatment. 2002 , 301, 625-30	51
1742	Anticancer activity of sodium stibogluconate in synergy with IFNs. 2002 , 169, 5978-85	63
1741	Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. 2002 , 86, 1162-8	38
1740	Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. 2002 , 86, 819-27	92
1739	Inhibition of the replication of a hepatitis C virus-like RNA template by interferon and 3'-deoxycytidine. 2002 , 13, 363-70	5
1738	Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: Enhancement by combination with interferon- β . 2002 , 20, 97	8
1737	Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. 2002 , 21, 361	2
1736	Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. 2002 , 1, 674-82	21
1735	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. 2002 , 13, 65-72	197
1734	Increased CD4 and CCR5 expression and human immunodeficiency virus type 1 entry in CD40 ligand-stimulated macrophages. 2002 , 185, 1567-77	11

1733	Chemotherapy: Synergism and Antagonism. 2002 , 473-484	3
1732	Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. 2002 , 46, 1640-6	48
1731	p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. 2002 , 16, 984-93	152
1730	Synergy determination issues. 2002 , 76, 10577; author reply 10578	12
1729	In vitro antiviral interaction of lopinavir with other protease inhibitors. 2002 , 46, 2249-53	49
1728	Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. 2002 , 94, 1010-9	45
1727	Interaction between p53 and p16 expressed by adenoviral vectors in human malignant glioma cell lines. 2002 , 97, 143-50	9
1726	The effect of DNA-alkylating agents on gene expression from two integrated reporter genes in a mouse mammary tumor line. 2002 , 13, 271-80	1
1725	Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines. 2002 , 13, 141-7	2
1724	Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. 2002 , 13, 29-36	20
1723	Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. 2002 , 13, 743-9	3
1722	Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. 2002 , 99, 3461-4	108
1721	Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. 2002 , 132, 3191-4	52
1720	Methodological issues related to antifungal drug interaction modelling for filamentous fungi. 2002 , 13, 101-117	11
1719	The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. 2002 , 277, 31-47	49
1718	In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. 2002 , 13, 1743-8	59
1717	Experimental application of the median-effect principle for in vitro quantification of the combined inhibitory activities of clavulanic acid and imipenem against IRT-4 beta-lactamase. 2002 , 19, 75-8	9
1716	Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. 2002 , 2, 182-8	8

1715	Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. 2002 , 20, 673-85	31
1714	XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. 2002 , 18, 989-97	38
1713	Calcitriol (1,25-Dihydroxycholecalciferol) Potentiates Activity of Mitoxantrone/Dexamethasone in an Androgen Independent Prostate Cancer Model. 2002 , 168, 756-761	49
1712	Cytotoxicity of arsenic trioxide to transitional carcinoma cells. 2002 , 60, 346-50	23
1711	Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. 2002 , 531, 415-20	40
1710	Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs <i>Prunella vulgaris</i> and <i>Rhizoma cibotte</i> . 2002 , 71, 1779-91	32
1709	Main targets of tetraaza macrocyclic copper complex on L1210 murine leukemia cells. 2002 , 16, 491-8	10
1708	Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydropyridine (CDHP) in human tumour cells. 2002 , 38, 1271-7	75
1707	Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. 2002 , 38, 1653-60	19
1706	N-(4-hydroxyphenyl)-retinamide selectively increases All-TRANS retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells. 2002 , 23, 279-86	3
1705	S-acyl-2-thioethyl (SATE) pronucleotides are potent inhibitors of HIV-1 replication in T-lymphoid cells cross-resistant to deoxycytidine and thymidine analogs. 2002 , 53, 143-52	13
1704	Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. 2002 , 55, 141-50	22
1703	Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid. 2002 , 63, 251-8	31
1702	Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. 2002 , 63, 1831-42	55
1701	3'-Azido-2',3'-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells. 2002 , 64, 239-46	15
1700	Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells. 2002 , 64, 481-5	22
1699	Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. 2002 , 64, 1215-26	19
1698	Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. 2002 , 38, 41-8	28

1697	Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. 2002 , 91, 1334-42	39
1696	Synthesis and enzymatic activation of N-[N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithiny]-L-phenylalanine, a candidate for antibody-directed enzyme prodrug therapy (ADEPT). 2002 , 10, 493-500	9
1695	Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. 2002 , 2, 6	53
1694	Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. 2002 , 119, 3-14	28
1693	Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. 2002 , 53, 140-5	40
1692	Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. 2002 , 51, 211-8	108
1691	Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. 2002 , 30, 135-40	37
1690	Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. 2002 , 16, 1213-9	90
1689	In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. 2002 , 16, 2096-105	60
1688	Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. 2002 , 16, 2349-57	77
1687	Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. 2002 , 21, 1882-9	60
1686	Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. 2002 , 86, 1487-93	40
1685	Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. 2002 , 72, 203-19	65
1684	Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. 2002 , 76, 157-66	66
1683	Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer. 2003 , 79, 301-12	32
1682	Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells. 2003 , 20, 957-61	25
1681	L-Canavanine as a radiosensitization agent for human pancreatic cancer cells. 2003 , 244, 37-43	16
1680	Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. 2003 , 51, 221-6	114

1679	Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. 2003 , 52, 41-6	25
1678	The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. 2003 , 52, 175-84	12
1677	The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. 2003 , 52, 442-8	61
1676	Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxytyl) and cytarabine in human leukemia cells. 2003 , 52, 497-506	12
1675	Combined use of nonmyelosuppressive nitrosourea analogues with hydroxyurea in the induction of F-cell production in a human erythroleukemic cell line. 2003 , 31, 592-600	5
1674	The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. 2003 , 27, 47-54	41
1673	Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. 2003 , 66, 551-63	38
1672	Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani. 2003 , 473, 9-17	164
1671	Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors. 2003 , 107, 155-61	16
1670	Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus amarus. 2003 , 58, 175-86	74
1669	Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. 2003 , 58, 209-15	92
1668	Aspirin-like molecules that inhibit human immunodeficiency virus 1 replication. 2003 , 58, 253-63	7
1667	Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity. 2003 , 103, 387-92	19
1666	Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. 2003 , 104, 504-11	184
1665	New analogues of AHMA as potential antitumor agents: synthesis and biological activity. 2003 , 11, 4959-69	21
1664	Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. 2003 , 57, 1075-83	58
1663	Non-classical antifolates, 5-(N-phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines and 2,4-Diamino-6(5H)-oxopyrimidines, synthesis and antitumor studies. 2003 , 11, 145-57	7
1662	1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. 2003 , 89, 746-53	56

1661	Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C. 2003 , 89, 2299-304	8
1660	Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. 2003 , 17, 1508-20	33
1659	The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. 2003 , 17, 2036-45	122
1658	Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. 2003 , 22, 6231-42	93
1657	Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. 2003 , 22, 7108-22	125
1656	Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. 2003 , 27, 617-26	25
1655	Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines. 2003 , 3, 367-73; discussion 373-4	5
1654	Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity. 2003 , 15, 472-9	6
1653	In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. 2003 , 40, 325-32	12
1652	Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment. 2003 , 189, 59-68	20
1651	Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells. 2003 , 189, 147-56	10
1650	The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro. 2003 , 39, 838-46	19
1649	Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. 2003 , 39, 1318-29	39
1648	Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. 2003 , 22, 1117-25	54
1647	Predictive Software for Drug Design and Development. 2003 , 1, 159-168	3
1646	Systematic discovery of multicomponent therapeutics. 2003 , 100, 7977-82	483
1645	Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV. 2003 , 14, 39-47	12
1644	APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro. 2003 , 51, 1181-9	2

1643	Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41. 2003 , 8, 685-93	47
1642	Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-L-glyceropent-2-enofuranosyl)cytosine. 2003 , 47, 1922-8	10
1641	Alpha interferon augments cidofovir's antiviral and antiproliferative activities. 2003 , 47, 2022-6	9
1640	Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. 2003 , 63, 862-9	64
1639	Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. 2003 , 19, 125-31	24
1638	In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. 2003 , 89, 2305-11	28
1637	Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. 2003 , 7, 731-40	34
1636	Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. 2003 , 89, 585-92	69
1635	Efficacy of targeted FasL in nasopharyngeal carcinoma. 2003 , 8, 964-73	24
1634	Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. 2003 , 89, 944-50	25
1633	Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4. 2003 , 19, 947-55	13
1632	IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis. 2003 , 23, 3-10	26
1631	Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. 2003 , 278, 39461-9	64
1630	Growth and DNA damage-inducible transcription factor 153 mediates apoptosis in response to fenretinide but not synergy between fenretinide and chemotherapeutic drugs in neuroblastoma. 2003 , 64, 1370-8	18
1629	Organophosphorus Insecticides Synergize Pyrethroids in the Resistant Strain of Cotton Bollworm, <i>Helicoverpa armigera</i> (Hbner) (Lepidoptera: Noctuidae) from West Africa. 2003 , 96, 468-474	51
1628	Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. 2003 , 22, 1057	2
1627	Enhanced antitumor activity of irifulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. 2003 , 23, 1347	3
1626	Synergistic anticancer action of reversibly and irreversibly acting ligands of poly (ADP-ribose) polymerase. 2003 , 11, 191	

- 1625 The multidrug resistance modulator SDZ-PSC 833 potentiates the photodynamic activity of chlorin e6 independently of P-glycoprotein in multidrug resistant human breast adenocarcinoma cells. **2003**, 22, 733 2
- 1624 Synergistic growth inhibitory effects of interferon- β and lovastatin on bcr-abl positive leukemic cells. **2003**, 23, 151
- 1623 Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. **2003**, 14, 242-7 14
- 1622 Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. **2003**, 102, 1824-32 84
- 1621 The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. **2003**, 102, 3765-74 245
- 1620 Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. **2003**, 133, 2669-74 154
- 1619 Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. **2003**, 133, 516-21 89
- 1618 The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro. **2003**, 44, 1549-55 10
- 1617 Dipyridamole increases the cytotoxicity of cisplatin in human larynx cancer cells in vitro. **2004**, 37, 591-9 13
- 1616 The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma. **2004**, 34, 499-504 15
- 1615 Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells. **2004**, 10, 7747-56 45
- 1614 Design of efficacy trials of cytokines in combination with antifungal drugs. **2004**, 39 Suppl 4, S218-23 29
- 1613 The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. **2004**, 10, 3562-71 51
- 1612 Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells. **2004**, 10, 1160-9 6
- 1611 Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. **2004**, 64, 8746-53 28
- 1610 Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines. **2004**, 15, 2893-901 30
- 1609 Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. **2004**, 96, 1536-48 61
- 1608 Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line. **2004**, 10, 4176-84 50

1607	The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. 2004 , 64, 2590-600	129
1606	The synthetic triterpenoid 2-cyano-3,12-dioxoleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. 2004 , 64, 7927-35	123
1605	Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. 2004 , 64, 2096-104	35
1604	Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. 2004 , 64, 8405-10	57
1603	Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. 2004 , 64, 3645-52	131
1602	Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. 2004 , 64, 5850-60	152
1601	Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. 2004 , 10, 1535-44	26
1600	Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. 2004 , 10, 3839-52	345
1599	Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. 2004 , 10, 1813-25	70
1598	Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. 2004 , 10, 1500-7	24
1597	Entry and fusion inhibitors of HIV. 2004 , 14, 733-748	4
1596	Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. 2004 , 53, 464-8	16
1595	Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. 2004 , 10, 2512-24	72
1594	Valproic acid and interferon- β synergistically inhibit neuroblastoma cell growth in vitro and in vivo. 2004 , 25, 1795	1
1593	The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. 2004 , 25, 1823	1
1592	CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. 2004 , 18, 2115-25	58
1591	TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. 2004 , 48, 4680-6	302
1590	Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. 2004 , 10, 4858-64	42

1589	Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. 2004 , 15, 141-51	71
1588	The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. 2004 , 64, 6626-34	208
1587	In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. 2004 , 10, 728-38	88
1586	Synergistic interactions between tamoxifen and trastuzumab (Herceptin). 2004 , 10, 1409-20	68
1585	Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. 2004 , 66, 113-21	69
1584	DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. 2004 , 65, 1496-506	50
1583	Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). 2004 , 18, 1001-3	59
1582	Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. 2004 , 64, 4957-64	89
1581	Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. 2004 , 10, 1059-70	24
1580	Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. 2004 , 10, 6487-501	257
1579	Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. 2004 , 11, 109-20	54
1578	Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. 2004 , 11, 547-54	21
1577	Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. 2004 , 18, 1699-704	75
1576	Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. 2004 , 18, 1780-8	60
1575	Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. 2004 , 18, 1951-63	53
1574	The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. 2004 , 23, 6900-13	69
1573	Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. 2004 , 23, 8941-9	22
1572	Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. 2004 , 93, 149-54	43

1571	Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. 2004 , 94, 107-14	49
1570	Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. 2004 , 4, 92	50
1569	Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. 2004 , 61, 101-9	81
1568	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). 2004 , 68, 135-44	48
1567	Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. 2004 , 68, 843-55	59
1566	Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). 2004 , 84, 183-95	63
1565	Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. 2004 , 86, 125-37	40
1564	Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines. 2004 , 22, 399-409	7
1563	Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. 2004 , 88, 141-8	34
1562	Expression of sigma 1 receptor in human breast cancer. 2004 , 87, 205-14	58
1561	The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. 2004 , 53, 296-304	24
1560	In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. 2004 , 53, 186-90	34
1559	Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells. 2004 , 54, 139-45	12
1558	Overexpression of alpha-synuclein decreased viability and enhanced sensitivity to prostaglandin E(2), hydrogen peroxide, and a nitric oxide donor in differentiated neuroblastoma cells. 2004 , 76, 415-22	15
1557	Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. 2004 , 58, 353-60	29
1556	Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line. 2004 , 23, 1513-6	6
1555	N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. 2004 , 48, 4349-59	224
1554	Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. 2004 , 96, 739-49	433

1553	Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. 2004 , 10, 7994-8004	317
1552	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa[ZD1839]). 2004 , 68, 135-135	
1551	Combination antifungal therapy. 2004 , 48, 693-715	412
1550	Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. 2004 ,	
1549	Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts. 2004 , 215, 53-9	99
1548	Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. 2004 , 40, 2837-44	23
1547	Anti-HCV activities of selective polyunsaturated fatty acids. 2004 , 318, 275-80	69
1546	Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. 2004 , 29, 27-32	10
1545	Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. 2004 , 10, 7031-42	280
1544	The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. 2004 , 64, 2343-6	465
1543	Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. 2004 , 37, 1543-9	52
1542	Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors. 2004 , 15, 849-60	6
1541	Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. 2004 , 15, 809-18	22
1540	Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. 2004 , 15, 371-6	30
1539	Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine [®])-induced cytotoxicity and apoptotic cell death in human breast cancer cells. 2004 , 12, 411	4
1538	Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. 2004 , 103, 2266-75	62
1537	Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. 2004 , 104, 4202-9	108
1536	In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. 2004 , 103, 208-15	88

1535	Inhibitory effect of imatinib on normal progenitor cells in vitro. 2004 , 103, 523-9	88
1534	Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. 2004 , 103, 1855-61	38
1533	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. 2004 , 103, 3158-66	106
1532	Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. 2004 , 103, 2761-70	96
1531	Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. 2004 , 104, 509-18	102
1530	In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. 2004 , 104, 1145-50	192
1529	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. 2004 , 104, 4188-93	167
1528	Ess polyunsaturated fatty acid Elinolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. 2004 , 11, 1241	4
1527	Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma. 2005 , 16, 945-51	12
1526	A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). 2005 , 28, 81-90	29
1525	Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. 2005 , 14, 683	1
1524	In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment. 2005 , 16, 417-22	18
1523	Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. 2005 , 14, 263-70	73
1522	Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells. 2005 , 16, 309-16	7
1521	Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. 2005 , 105, 3303-11	209
1520	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. 2005 , 105, 2099-106	38
1519	Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. 2005 , 106, 318-27	110
1518	Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. 2005 , 105, 3270-7	29

1517	Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. 2005 , 106, 1042-7	152
1516	MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. 2005 , 106, 3150-9	313
1515	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. 2005 , 106, 706-12	52
1514	The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. 2005 , 106, 4322-9	52
1513	5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. 2005 , 9, 1068-77; discussion 1077-9	47
1512	Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. 2005 , 61, 535-42	44
1511	Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity. 2005 , 13, 3993-4006	29
1510	Synthesis and antitumor activity of 5-(9-acridinylamino)anisidine derivatives. 2005 , 13, 6513-20	27
1509	Preclinical modeling of combination treatments: fantasy or requirement?. 2005 , 1059, 61-9	21
1508	Algal toxicity of nitrobenzenes: combined effect analysis as a pharmacological probe for similar modes of interaction. 2005 , 24, 324-33	66
1507	Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. 2005 , 130, 912-25	36
1506	Potential of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. 2005 , 131, 219-22	11
1505	Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. 2005 , 92, 722-8	27
1504	Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. 2005 , 92, 2266-77	48
1503	Multicomponent therapeutics for networked systems. 2005 , 4, 71-8	583
1502	Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. 2005 , 19, 234-44	44
1501	Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells. 2005 , 19, 595-602	23
1500	Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. 2005 , 19, 1198-206	86

1499	Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. 2005 , 19, 1835-8	24
1498	Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. 2005 , 19, 1579-89	61
1497	Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. 2005 , 19, 1648-55	57
1496	Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. 2005 , 19, 1896-904	51
1495	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. 2005 , 24, 6861-9	240
1494	Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. 2005 , 7, 575-89	413
1493	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. 2005 , 8, 407-19	611
1492	Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. 2005 , 33, 329-35	36
1491	Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. 2005 , 33, 542-9	11
1490	PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. 2005 , 33, 784-95	48
1489	Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases. 2005 , 130, 125-30	15
1488	Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. 2005 , 5, 103	18
1487	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. 2005 , 115, 19-35	88
1486	Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. 2005 , 117, 670-82	53
1485	In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. 2005 , 55, 595-601	16
1484	In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines. 2005 , 56, 279-85	8
1483	Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice. 2005 , 56, 379-90	32
1482	Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. 2005 , 10, 1411-8	62

1481	Application of median-effect in quantitative analysis of antitumor drugs in vitro. 2005 , 17, 140-144	1
1480	Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors. 2005 , 11, 97-103	31
1479	Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. 2005 , 4, 457-70	57
1478	Models for Drug Development and Drug Resistance. 2005 ,	
1477	Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. 2005 , 3, 277-85	106
1476	Potentialiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells. 2005 , 4, 1772-85	26
1475	Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. 2005 , 16 Suppl 4, iv61-68	91
1474	Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. 2005 , 4, 1962-71	23
1473	Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. 2005 , 65, 3162-70	145
1472	Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. 2005 , 11, 4225-33	23
1471	TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. 2005 , 49, 3483-5	30
1470	[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. 2005 , 11, 7929-37	54
1469	Potentialiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. 2005 , 4, 1328-37	62
1468	A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. 2005 , 65, 9517-24	26
1467	Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. 2005 , 4, 587-94	99
1466	Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. 2005 , 11, 6065-74	50
1465	The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. 2005 , 280, 14349-55	87
1464	Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. 2005 , 33, 1249-56	148

1463	The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. 2005 , 11, 4589-600	27
1462	Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 2005 , 12, 1051-8	30
1461	Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. 2005 , 68, 1551-8	75
1460	Time-dependent modulation of thioredoxin reductase activity might contribute to sulforaphane-mediated inhibition of NF-kappaB binding to DNA. 2005 , 7, 1601-11	52
1459	Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. 2005 , 105, 1768-76	299
1458	Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. 2005 , 92, 1063-8	43
1457	Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. 2005 , 102, 4584-9	445
1456	Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. 2005 , 280, 11259-73	183
1455	A fascination with enzymes: the journey not the arrival matters. 2005 , 280, 28829-47	10
1454	Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. 2005 , 49, 1830-6	60
1453	Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. 2005 , 11, 7480-9	82
1452	Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. 2005 , 65, 9436-44	76
1451	Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. 2005 , 65, 2364-72	24
1450	Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. 2005 , 65, 8951-60	59
1449	SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. 2005 , 65, 10381-8	66
1448	The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells. 2005 , 51, 93-102	23
1447	Bexarotene and erlotinib for aerodigestive tract cancer. 2005 , 23, 8757-64	58
1446	Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. 2005 , 67, 1166-76	74

1445	Combination of 5-fluorouracil and N1,N11-diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma cells. 2005 , 280, 3295-304	44
1444	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. 2005 , 19, 960-2	56
1443	Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. 2005 , 65, 5848-56	39
1442	Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. 2005 , 4, 1358-63	54
1441	Growth and molecular interactions between tamoxifen and trastuzumab. 2005 , 11, 3597; author reply 3597-9	
1440	Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: Induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms. 2005 , 27, 553	
1439	Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines. 2005 , 69, 224-38	13
1438	Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells. 2005 , 26, 1569	3
1437	Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelson, via parenteral or oral route. 2005 , 65, 9445-54	40
1436	Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. 2005 , 4, 1159-67	20
1435	Potential of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. 2005 , 4, 866-71	13
1434	Antitumoral actions of the anti-obesity drug orlistat (Xenical TM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. 2005 , 16, 1253-67	120
1433	Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. 2005 , 7, 921-9	80
1432	Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53. 2005 , 164, 642-50	22
1431	Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. 2005 , 65, 1561-9	188
1430	Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. 2005 , 105, 4021-7	57
1429	Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. 2005 , 65, 2422-32	179
1428	The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. 2005 , 389, 517-26	130

1427	Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. 2005 , 25, 632-49	28
1426	Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies. 2005 , 210, 639-45	10
1425	Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. 2005 , 1723, 270-81	117
1424	Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. 2005 , 326, 905-8	176
1423	Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. 2005 , 331, 391-7	27
1422	Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. 2005 , 218, 141-51	221
1421	Potential by alpha-tocopheryl succinate of the etoposide response in multidrug resistance protein 1-expressing glioblastoma cells. 2005 , 217, 181-90	15
1420	Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. 2005 , 222, 173-81	32
1419	Inhibitors of arachidonic acid metabolism act synergistically to signal apoptosis in neoplastic cells. 2005 , 73, 463-74	21
1418	Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. 2005 , 23, 1170-7	27
1417	Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. 2005 , 80, 409-16; discussion 416-7	45
1416	Spectrum of antiviral activity of o-(acetoxyphenyl)hept-2-ynyl sulphide (APHS). 2005 , 25, 419-26	3
1415	The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. 2005 , 50, 9-18	42
1414	Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. 2005 , 174, 741-6	25
1413	Novel Disulfides with Antitumour Efficacy and Specificity. 2005 , 58, 128	10
1412	Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. 2006 , 8, R2	12
1411	Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. 2005 , 7, R1097-110	47
1410	Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. 2005 , 7, R681-9	56

1409	Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. 2006 , 5, 160-9	158
1408	MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. 2006 , 107, 4109-14	204
1407	Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. 2006 , 58, 621-81	3355
1406	Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. 2006 , 5, 2378-87	96
1405	Colchicine glycorandomization influences cytotoxicity and mechanism of action. 2006 , 128, 14224-5	82
1404	Resveratrol, an ingredient of wine, acts synergistically with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. 2006 , 25, 1019-24	5
1403	Identification of the HIV-1 gp41 core-binding motif--HXXNPF. 2006 , 580, 4807-14	16
1402	Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. 2006 , 5, 1854-63	263
1401	P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. 2006 , 84, 1022-33	32
1400	The use of brequinar sodium for transplantation. 1993 , 696, 216-26	6
1399	Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. 2006 , 175, 1926-31	56
1398	Bleomycin has antiviral properties against drug-resistant HIV strains and sensitises virus to currently used antiviral agents. 2006 , 27, 63-8	3
1397	Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. 2006 , 53, 13-21	19
1396	Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. 2006 , 3, 457-67	40
1395	Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. 2006 , 49, 2151-4	65
1394	Distinct cytotoxic mechanisms of pristine versus hydroxylated fullerene. 2006 , 91, 173-83	239
1393	Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. 2006 , 5, 2778-86	79
1392	Identification of a D-amino acid decapeptide HIV-1 entry inhibitor. 2006 , 347, 909-15	6

1391	Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. 2006 , 348, 1245-53	48
1390	Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells. 2006 , 233, 240-6	7
1389	Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. 2006 , 42, 91-6	55
1388	Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. 2006 , 78, 2494-502	40
1387	Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41. 2006 , 364, 283-9	22
1386	Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. 2006 , 25, 440-6	29
1385	Gastric mucosal cell model for estimating relative gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. 2006 , 75, 9-17	15
1384	Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function. 2006 , 38, 3479-82	6
1383	Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. 2006 , 3, e237	456
1382	In vitro antiviral activity of marine sponges collected off Brazilian coast. 2006 , 29, 135-40	35
1381	Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. 2006 , 107, 1546-54	86
1380	Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. 2006 , 107, 3683-92	48
1379	Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. 2006 , 107, 285-92	28
1378	The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. 2006 , 107, 232-40	90
1377	Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress. 2006 , 107, 241-9	32
1376	PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. 2006 , 107, 752-9	203
1375	Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. 2006 , 108, 630-7	157
1374	Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). 2006 , 107, 4122-9	150

1373	Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. 2006 , 108, 645-52	127
1372	The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. 2006 , 108, 3494-503	101
1371	Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. 2006 , 108, 3441-9	300
1370	Selective leukemic-cell killing by a novel functional class of thalidomide analogs. 2006 , 108, 4126-35	25
1369	Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. 2006 , 108, 3504-13	64
1368	Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. 2006 , 17, 631-9	1
1367	In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines. 2006 , 17, 445-53	13
1366	Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. 2006 , 17, 377-84	23
1365	Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. 2006 , 17, 807-13	4
1364	Combination effect of mycophenolate mofetil with mizoribine on cell proliferation assays and in a mouse heart transplantation model. 2006 , 82, 175-9	12
1363	Potential synergism of natural products in the treatment of cancer. 2006 , 20, 239-49	177
1362	Could resistance to insecticides in <i>Plutella xylostella</i> (Lep., Plutellidae) be overcome by insecticide mixtures?. 2006 , 130, 122-127	63
1361	Prediction of activity, synthesis and biological testing of anti-HSV active peptides. 2006 , 68, 58-66	8
1360	A generalized response surface model with varying relative potency for assessing drug interaction. 2006 , 62, 986-95	41
1359	Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. 2006 , 135, 52-61	18
1358	Iron enhances endothelial cell activation in response to Cytomegalovirus or <i>Chlamydia pneumoniae</i> infection. 2006 , 36, 743-52	15
1357	Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. 2006 , 97, 945-51	47
1356	ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib. 2006 , 97, 1404-9	15

1355	Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. 2006 , 97, 1388-95	18
1354	Allosteric inhibitors of Bcr-abl-dependent cell proliferation. 2006 , 2, 95-102	298
1353	Systems biology and combination therapy in the quest for clinical efficacy. 2006 , 2, 458-66	428
1352	Integration of EGFR inhibitors with radiochemotherapy. 2006 , 6, 876-85	233
1351	NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. 2006 , 95, 1653-62	51
1350	Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity. 2006 , 13, 203-14	22
1349	Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. 2006 , 13, 1534-44	37
1348	Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. 2006 , 20, 610-9	34
1347	c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. 2006 , 25, 838-48	176
1346	RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin. 2006 , 30, 553-60	9
1345	HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24. 2006 , 30, 1005-11	24
1344	Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. 2006 , 30, 1263-72	26
1343	Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells. 2006 , 30, 1447-51	6
1342	Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. 2007 , 14, 258-69	40
1341	Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. 2006 , 23, 336-49	24
1340	Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. 2006 , 96, 217-25	13
1339	Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma. 2006 , 57, 105-13	22
1338	Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. 2006 , 57, 171-9	9

1337	In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. 2006 , 57, 709-18	81
1336	Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. 2006 , 58, 13-23	104
1335	Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. 2006 , 58, 210-8	20
1334	The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. 2006 , 58, 219-28	23
1333	Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. 2006 , 58, 640-53	22
1332	JWA, a novel signaling molecule, involved in all-trans retinoic acid induced differentiation of HL-60 cells. 2006 , 13, 357-71	16
1331	Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. 2006 , 353, 184-92	43
1330	Cytotoxic and biochemical effects of 3,3',4,4',5,5'-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. 2006 , 34, 1377-84	39
1329	The nitroxide Tempol modulates anthracycline resistance in breast cancer cells. 2006 , 40, 1409-18	18
1328	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. 2006 , 10, 375-88	820
1327	Enhancement of antinociception by co-administration of ibuprofen and caffeine in arthritic rats. 2006 , 544, 31-8	30
1326	A rapid quantitative PCR-based assay for testing antiviral agents against human adenoviruses demonstrates type specific differences in ribavirin activity. 2006 , 72, 34-41	15
1325	Statistical analysis of combined dose effects for experiments with two agents. 2006 , 37, 65-71	6
1324	Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. 2006 , 71, 751-60	33
1323	Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. 2006 , 72, 941-8	38
1322	The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells. 2006 , 215, 317-29	7
1321	A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. 2006 , 111, 153-64	114
1320	The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. 2006 , 6, 142	16

1319	The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. 2006 , 207, 420-7	113
1318	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. 2006 , 208, 344-53	54
1317	Different anti-HCV profiles of statins and their potential for combination therapy with interferon. 2006 , 44, 117-25	261
1316	Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. 2006 , 118, 773-9	56
1315	Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. 2007 , 120, 1141-9	15
1314	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. 2006 , 45, 288-301	25
1313	Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells. 2006 , 45, 47-59	37
1312	Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. 2006 , 5, 2237-43	24
1311	Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. 2006 , 66, 9957-66	30
1310	Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells. 2006 , 5, 1342-51	48
1309	Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2. 2006 , 5, 1294-303	8
1308	Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. 2006 , 5, 48-53	51
1307	Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. 2006 , 91, 79-84	35
1306	Actein and a fraction of black cohosh potentiate antiproliferative effects of chemotherapy agents on human breast cancer cells. 2006 , 72, 1200-6	39
1305	Laboratory evaluation of pyriproxyfen and spinosad, alone and in combination, against <i>Aedes aegypti</i> larvae. 2006 , 43, 1190-4	31
1304	Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. 2006 , 5, 1577-84	7
1303	Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. 2006 , 66, 5836-46	75
1302	Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. 2006 , 12, 5869-78	86

1301	Potential of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. 2006 , 5, 1197-208	84
1300	Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. 2006 , 12, 6547-56	32
1299	Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. 2006 , 4, 549-62	59
1298	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. 2006 , 5, 1154-65	79
1297	Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. 2006 , 5, 3042-51	51
1296	Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. 2006 , 27, 508-16	106
1295	Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. 2006 , 24, 3735-46	62
1294	Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. 2006 , 5, 2211-7	45
1293	Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. 2006 , 5, 645-54	49
1292	Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. 2006 , 98, 38-50	125
1291	Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. 2006 , 12, 617-25	77
1290	Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. 2006 , 12, 6540-6	20
1289	Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. 2006 , 319, 1070-80	89
1288	A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. 2006 , 66, 10959-66	88
1287	Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. 2006 , 5, 919-26	40
1286	Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. 2006 , 12, 5578-86	136
1285	Novel combinations based on epidermal growth factor receptor inhibition. 2006 , 12, 4446s-4450s	33
1284	The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. 2006 , 5, 2522-30	94

1283	Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. 2006 , 52, 23-8	118
1282	Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). 2006 , 5, 776-85	69
1281	Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. 2006 , 12, 591-9	83
1280	Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. 2006 , 12, 2856-61	10
1279	Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. 2006 , 12, 5199-206	86
1278	Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. 2006 , 5, 3248-57	53
1277	Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera. 2006 , 20, 353-5	58
1276	Laboratory Evaluation of Pyriproxyfen and Spinosad, Alone and in Combination, Against <i>Aedes aegypti</i> Larvae. 2006 , 43, 1190-1194	48
1275	Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. 2006 , 70, 1534-41	64
1274	Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. 2006 , 50, 3289-96	85
1273	Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. 2006 , 5, 2013-22	21
1272	Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. 2006 , 66, 7245-52	97
1271	Farnesyltransferase inhibitors reverse taxane resistance. 2006 , 66, 8838-46	26
1270	Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. 2006 , 66, 404-11	84
1269	Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. 2006 , 94, 1837-44	33
1268	The interaction between two radiosensitizers: 5-iododeoxyuridine and caffeine. 2006 , 66, 490-8	11
1267	Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. 2006 , 5, 1559-70	87
1266	Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. 2006 , 66, 7059-66	129

1265	In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. 2006 , 50, 625-31	40
1264	The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). 2006 , 69, 1207-15	53
1263	Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. 2007 , 67, 1176-83	267
1262	The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. 2007 , 13, 621-9	111
1261	Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. 2007 , 13, 4233-44	54
1260	Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. 2007 , 5, 1133-45	62
1259	S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. 2007 , 6, 1368-78	25
1258	Hyperglycemia-induced thioredoxin-interacting protein expression differs in breast cancer-derived cells and regulates paclitaxel IC50. 2007 , 13, 3724-30	19
1257	5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. 2007 , 6, 1718-27	142
1256	Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. 2007 , 25, 5225-32	273
1255	Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. 2007 , 67, 11300-8	79
1254	Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. 2007 , 96, 231-40	40
1253	Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. 2007 , 96, 21-8	22
1252	Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. 2007 , 18, 51-62	23
1251	Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. 2007 , 97, 253-9	20
1250	Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. 2007 , 92, 1451-9	81
1249	Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells. 2007 , 6, 2310-8	12
1248	Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure. 2007 , 5, 773-82	27

1247	Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. 2007 , 13, 1036-44	51
1246	A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. 2007 , 81, 12946-53	35
1245	Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. 2007 , 99, 1107-19	70
1244	Quantitative combination effects between sulforaphane and 3,3'-diindolylmethane on proliferation of human colon cancer cells in vitro. 2007 , 28, 1471-7	59
1243	Effect of cytarabine and decitabine in combination in human leukemic cell lines. 2007 , 13, 4225-32	97
1242	Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. 2007 , 6, 246-52	32
1241	In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors. 2007 , 6, 898-906	28
1240	Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. 2007 , 6, 1544-51	40
1239	Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. 2007 , 6, 2664-74	41
1238	Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy. 2007 , 6, 510-8	9
1237	Cytotoxic and anti-HIV-1 caged xanthenes from the resin and fruits of <i>Garcinia hanburyi</i> . 2007 , 73, 33-40	70
1236	Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. 2007 , 106, 407-16	23
1235	Anti HIV-1 flavonoid glycosides from <i>Ochna integerrima</i> . 2007 , 73, 683-8	33
1234	Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. 2007 , 96, 1223-33	148
1233	Novel inhibitors of the early steps of the HIV-1 life cycle. 2007 , 16, 11-23	7
1232	Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis. 2007 , 18, 435-50	17
1231	HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. 2007 , 104, 19482-7	189
1230	Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. 2007 , 92, 4712-8	90

1229	The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. 2007 , 67, 9490-500	101
1228	Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. 2007 , 13, 7155-65	68
1227	Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. 2007 , 6, 692-702	61
1226	Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. 2007 , 13, 4280-90	59
1225	Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. 2007 , 67, 3239-53	118
1224	A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. 2007 , 13, 4178-84	33
1223	Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. 2007 , 13, 3413-22	171
1222	Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. 2007 , 83, 338-43	40
1221	The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. 2007 , 6, 128-37	42
1220	Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. 2007 , 282, 29831-46	95
1219	The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. 2007 , 13, 7191-8	88
1218	Antiviral and cellular metabolism interactions between Dixelvucitabine and lamivudine. 2007 , 51, 2130-5	10
1217	Potential of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. 2007 , 6, 1951-61	71
1216	The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo. 2007 , 6, 2409-17	34
1215	Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. 2007 , 282, 6143-52	39
1214	The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins. 2007 , 50, 156-60	13
1213	The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. 2007 , 6, 2458-67	36
1212	Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling. 2007 , 13, 2261-70	18

1211	Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. 2007 , 6, 2515-24	106
1210	CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. 2007 , 72, 18-28	40
1209	Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. 2007 , 13, 1140-8	68
1208	Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer. 2007 , 13, 6827-33	20
1207	Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy. 2007 , 53, 218-25	5
1206	Synergism between cis-permethrin and benzoyl phenyl urea insect growth regulators against <i>Aedes aegypti</i> larvae. 2007 , 23, 24-8	4
1205	Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. 2007 , 67, 11499-504	108
1204	Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. 2007 , 6, 61-9	48
1203	Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand. 2007 , 5, 615-25	36
1202	Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. 2007 , 28, 1217-23	59
1201	The concurrent chemoradiation paradigm--general principles. 2007 , 4, 86-100	301
1200	Anti-proliferative and antioxidant activities of <i>Saposhnikovia divaricata</i> . 2007 ,	5
1199	In vitro combination characterization of the new anticancer plant drug Elemene with taxanes against human lung carcinoma. 2007 ,	3
1198	The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation. 2007 , 403, 565-71	16
1197	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. 2007 , 110, 278-86	224
1196	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. 2007 , 110, 1656-63	103
1195	Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. 2007 , 109, 1701-11	84
1194	NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. 2007 , 110, 267-77	179

1193	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). 2007 , 109, 1220-7	140
1192	MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. 2007 , 109, 2121-9	36
1191	Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. 2007 , 109, 3031-41	60
1190	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. 2007 , 109, 4441-9	177
1189	Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. 2007 , 109, 4415-23	60
1188	Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. 2007 , 110, 661-9	36
1187	Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. 2007 , 110, 2075-83	105
1186	AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. 2007 , 110, 2034-40	224
1185	Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. 2007 , 110, 2057-66	130
1184	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. 2007 ,	1
1183	Carrageenan/MIV-150 (PC-815), a combination microbicide. 2007 , 34, 9-14	78
1182	Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. 2007 , 18, 677-86	19
1181	Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. 2007 , 18, 781-91	11
1180	Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial. 2007 , 25, 207-13	2
1179	Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. 2007 , 43, 175-83	28
1178	In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. 2007 , 65, 289-99	29
1177	Interaction of insecticides with mammalian P-glycoprotein and their effect on its transport function. 2007 , 1768, 1750-7	45
1176	Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. 2007 , 245, 156-62	108

1175	Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine. 2007 , 250, 311-22	19
1174	Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. 2007 , 253, 124-30	71
1173	AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation. 2007 , 257, 36-46	15
1172	Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. 2007 , 258, 181-8	71
1171	Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. 2007 , 138, 37-44	54
1170	Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. 2007 , 46, 222-9	60
1169	SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. 2007 , 170, 366-76	125
1168	Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. 2007 , 13, 1611-9	166
1167	Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. 2007 , 109, 2112-20	93
1166	Interaction index and different methods for determining drug interaction in combination therapy. 2007 , 17, 461-80	103
1165	Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. 2007 , 81, 3005-8	29
1164	Nonlinear blending: a useful general concept for the assessment of combination drug synergy. 2007 , 27, 125-46	36
1163	On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. 2007 , 22, 201-33	18
1162	Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines. 2007 , 55, 49-56	15
1161	N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: Synergistic antitumor activity with arabinofuranosylcytosine. 2007 ,	
1160	Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status. 2007 , 92, 1286-8	11
1159	Synergy Effect of Vitamin K3 on Cytotoxicity of Camptothecin in HCT116 Cells. 2007 , 15, 54-60	1
1158	Models for Drug Development and Drug Resistance. 2007 ,	1

1157	Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. 2007 , 120, 2028-33	45
1156	TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. 2007 , 121, 431-41	25
1155	Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma. 2007 , 121, 1600-8	21
1154	Melissoidesin G, a diterpenoid purified from <i>Isodon melissoides</i> , induces leukemic-cell apoptosis through induction of redox imbalance and exhibits synergy with other anticancer agents. 2007 , 121, 2084-94	16
1153	Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells. 1994 , 56, 113-8	12
1152	R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. 2007 , 211, 533-43	55
1151	Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics. 2007 , 212, 710-6	9
1150	Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. 2007 , 46, 534-42	73
1149	Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. 2007 , 35, 205-20	64
1148	Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. 2007 , 7, 5	38
1147	Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. 2007 , 26, 652-61	86
1146	Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. 2007 , 26, 1920-31	33
1145	A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. 2007 , 26, 2374-80	194
1144	Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. 2007 , 26, 5793-807	85
1143	Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment. 2007 , 14, 627-39	21
1142	Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. 2007 , 14, 756-61	55
1141	The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. 2007 , 21, 739-46	30
1140	ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. 2007 , 21, 1549-60	131

1139	BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. 2007 , 21, 1763-72	84
1138	Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity. 2007 , 21, 2399-405	11
1137	Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. 2007 , 97, 628-36	25
1136	R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. 2007 , 97, 1344-53	82
1135	Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. 2007 , 99, 1539-45	14
1134	Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. 2007 , 138, 467-78	40
1133	The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. 2007 , 139, 385-97	109
1132	Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. 2007 , 139, 837-44	20
1131	Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo. 2007 , 98, 447-54	17
1130	Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. 2007 , 98, 2002-8	13
1129	3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line. 2007 , 5, 47-58	6
1128	Synergistic activity of troxacitabine (Troxytyl) and gemcitabine in pancreatic cancer. 2007 , 7, 121	25
1127	EGFR associated expression profiles vary with breast tumor subtype. 2007 , 8, 258	208
1126	Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. 2007 , 1773, 1095-106	117
1125	The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. 2007 , 73, 1548-57	19
1124	Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. 2007 , 35, 75-83	30
1123	Multi-target therapeutics: when the whole is greater than the sum of the parts. 2007 , 12, 34-42	789
1122	Aloe emodin inhibits the cytotoxic action of tumor necrosis factor. 2007 , 568, 248-59	32

1121	The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines. 2007 , 105, 462-9	21
1120	Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. 2008 , 80, 133-42	92
1119	Reversal of multidrug resistance in cancer cells by Rhizoma Alismatis extract. 2007 , 14, 160-5	52
1118	Toxicity interaction of metals (Ag, Cu, Hg, Zn) to urease and dehydrogenase activities in soils. 2007 , 39, 2329-2338	125
1117	Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. 2007 , 122, 39-46	197
1116	Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. 2007 , 47, 357-400	203
1115	Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. 2007 , 59, 749-57	12
1114	Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. 2007 , 60, 91-102	11
1113	Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. 2007 , 60, 245-55	60
1112	R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. 2007 , 60, 545-53	15
1111	Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model. 2007 , 60, 651-60	7
1110	Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines. 2007 , 60, 703-11	30
1109	Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. 2008 , 61, 179-88	39
1108	The combined effects of multiple chemotherapeutic agents for malignant glioma cells. 2007 , 84, 31-7	6
1107	AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. 2007 , 102, 275-82	12
1106	Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. 2007 , 106, 319-31	17
1105	Comparison of the rapid pro-apoptotic effect of trans-beta-nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells. 2007 , 12, 235-46	12
1104	SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. 2007 , 12, 1327-38	101

1103	15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation. 2007 , 12, 2101-14	32
1102	Synergy between verapamil and other multidrug -resistance modulators in model membranes. 2007 , 32, 737-46	9
1101	Synergistic antitumor efficacy of oncolytic adenovirus combined with chemotherapy. 2007 , 19, 76-81	1
1100	Mechanism of suppression on proliferation of QGY cell by oxaliplatin. 2007 , 19, 263-268	
1099	Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. 2008 , 112, 25-33	34
1098	Modulation of tumor necrosis factor-mediated cell death by fullerenes. 2008 , 25, 1365-76	17
1097	Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. 2008 , 25, 2056-64	23
1096	The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro. 2008 , 26, 195-204	28
1095	The combination of gamma ionizing radiation and 8-Cl-cAMP induces synergistic cell growth inhibition and induction of apoptosis in human prostate cancer cells. 2008 , 26, 309-17	9
1094	Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. 2008 , 57, 1849-59	129
1093	A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. 2008 , 61, 525-34	98
1092	Mechanistic study of potentiation of chemotherapy by a haloenol lactone derivative in vitro. 2008 , 62, 117-22	1
1091	Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. 2008 , 62, 305-13	87
1090	Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft. 2008 , 62, 621-9	19
1089	An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. 2008 , 62, 769-78	31
1088	Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. 2008 , 62, 821-30	37
1087	Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. 2008 , 42, 84-105	30
1086	Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. 2008 , 8, 3	29

1085	Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. 2008 , 27, 1040-61	46
1084	Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses. 2008 , 27, 3071-83	30
1083	Fitting models for the joint action of two drugs using SAS. 2008 , 7, 272-84	10
1082	Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models. 2008 , 22, 1125-32	42
1081	Alpha-hederin potentiates 5-FU antitumor activity in human colon adenocarcinoma cells. 2008 , 22, 1299-302	16
1080	Synergistic effect of three benzopyrans isolated from <i>Hypericum polyanthemum</i> in U-373 MG glioblastoma cell line. 2008 , 22, 1577-80	9
1079	Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. 2008 , 2, 908-14	17
1078	Potential of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells. 2008 , 68, 679-89	6
1077	Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. 2008 , 50, 757-60	3
1076	Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment. 2008 , 97, 1508-18	15
1075	Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. 2008 , 47, 446-57	47
1074	Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. 2008 , 122, 2115-24	78
1073	Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. 2008 , 122, 2148-53	49
1072	Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. 2008 , 123, 1005-14	86
1071	Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. 2008 , 123, 1536-44	27
1070	Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. 2008 , 123, 2774-81	57
1069	Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. 2008 , 123, 2939-49	34
1068	Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. 2008 , 87, 147-55	35

1067	Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. 2008 , 104, 595-605	6
1066	Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. 2008 , 215, 827-36	29
1065	Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice. 2008 , 48, 828-40	11
1064	Potential of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. 2008 , 32, 771-80	50
1063	MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. 2008 , 32, 1382-92	71
1062	Antiglioma action of xanthenes from <i>Gentiana kochiana</i> : Mechanistic and structure-activity requirements. 2008 , 16, 5683-94	28
1061	Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. 2008 , 16, 5413-23	54
1060	Development of pyrrole-imidazole polyamide for specific regulation of human aurora kinase-A and -B gene expression. 2008 , 15, 829-41	20
1059	(+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation. 2007 , 64, 261-298	54
1058	Design and photophysical properties of new RGD targeted tetraphenylchlorins and porphyrins. 2008 , 64, 3494-3504	25
1057	Self-assembled star-shaped chlorin-core poly(epsilon-caprolactone)-poly(ethylene glycol) diblock copolymer micelles for dual chemo-photodynamic therapies. 2008 , 29, 3599-608	146
1056	Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs. 2008 , 351, 259-70	25
1055	Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. 2008 , 14, 3571-81	115
1054	Benomyl and colchicine synergistically inhibit cell proliferation and mitosis: evidence of distinct binding sites for these agents in tubulin. 2008 , 47, 13016-25	36
1053	Modelling the anti-herpes simplex virus activity of small cationic peptides using amino acid descriptors. 2008 , 66, 48-56	3
1052	A semiparametric response surface model for assessing drug interaction. 2008 , 64, 396-405	25
1051	Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect. 2008 , 15, 535-42	8
1050	P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. 2008 , 27, 4161-71	31

1049	EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. 2008 , 99, 1-5	44
1048	Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. 2008 , 99, 473-80	18
1047	Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. 2008 , 99, 750-9	40
1046	Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. 2008 , 99, 1808-15	34
1045	Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. 2008 , 153, 1003-10	27
1044	Combination chemical genetics. 2008 , 4, 674-81	142
1043	Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. 2008 , 14, 762-6	249
1042	Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. 2008 , 128, 988-98	24
1041	The Hill equation: a review of its capabilities in pharmacological modelling. 2008 , 22, 633-48	479
1040	Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. 2008 , 102, 1458-66	15
1039	Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. 2008 , 99, 1218-26	55
1038	Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication. 2008 , 141, 454-60	15
1037	Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. 2008 , 141, 483-93	38
1036	Fatty acid synthase is a novel therapeutic target in multiple myeloma. 2008 , 141, 659-71	27
1035	Costs and benefits of multiple resistance to insecticides for <i>Culex quinquefasciatus</i> mosquitoes. 2008 , 8, 104	91
1034	Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. 2008 , 8, 65	19
1033	R(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. 2008 , 36, 568-76	47
1032	Dependence of trans-ADP-ribosylation and nuclear glycolysis on the Arg 34-ATP complex of Zn ²⁺ finger I of poly-ADP-ribose polymerase-1. 2008 , 582, 2709-13	1

1031	Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. 2008 , 75, 427-37	30
1030	The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. 2008 , 75, 836-46	19
1029	Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. 2008 , 75, 1035-44	44
1028	STI571/doxorubicin concentration-dependent switch for diverse caspase actions in CML cell line K562. 2008 , 75, 1761-73	17
1027	Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: characterization of a novel nucleobase transport activity. 2008 , 75, 1901-11	8
1026	Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. 2008 , 591, 43-51	95
1025	STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis. 2008 , 596, 41-9	21
1024	Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases. 2008 , 80, 407-18	11
1023	Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. 2008 , 81, 344-53	25
1022	Structure-function relationships of anthocyanins from various anthocyanin-rich extracts on the inhibition of colon cancer cell growth. 2008 , 56, 9391-8	190
1021	Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. 2008 , 7, 40	50
1020	The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. 2008 , 10, R56	39
1019	Bra1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. 2008 , 10, R10	467
1018	Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. 2008 , 10, 587-96	27
1017	Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. 2008 , 1, 36-43	22
1016	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK). 2008 , 51, 7689-96	19
1015	Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma. 2008 , 110, 244-54	30
1014	Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. 2008 , 469, 220-31	48

1013	Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy. 2008 , 35 Suppl 1, S9-20	16
1012	Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. 2008 , 22, 899-909	50
1011	SHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. 2008 , 259, 198-208	60
1010	Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. 2008 , 261, 205-14	22
1009	Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro. 2008 , 263, 302-11	45
1008	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. 2008 , 272, 296-306	104
1007	Toxicity interactions of cadmium, copper, and lead on soil urease and dehydrogenase activity in relation to chemical speciation. 2008 , 70, 1-9	47
1006	Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. 2008 , 18, 487-96	47
1005	Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. 2008 , 14, 4981-8	59
1004	Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?. 2008 , 86, 428-34	27
1003	Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. 2008 , 82, 8487-99	42
1002	Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. 2008 , 10, 597-603	37
1001	Experimental treatment of neuroblastoma using [¹³¹ I]meta-iodobenzylguanidine and topotecan in combination. 2008 , 81 Spec No 1, S28-35	20
1000	Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. 2008 , 105, 11317-22	114
999	Combination chemotherapy and photodynamic therapy with Fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. 2008 , 5, 696-709	52
998	Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. 2008 , 16, 487-93	97
997	Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. 2008 , 47, 13686-98	88
996	Preclinical versus clinical drug combination studies. 2008 , 49, 2059-80	187

995	Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation. 2008 , 283, 23721-30	21
994	3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. 2008 , 197, 42-5	19
993	Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol. 2008 , 74, 872-83	10
992	BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. 2008 , 68, 2944-51	110
991	Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors. 2008 , 52, 1862-4	36
990	The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. 2008 , 14, 8102-11	42
989	Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines. 2008 , 74, 724-35	8
988	Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclox). 2008 , 68, 3413-20	236
987	Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. 2008 , 68, 9394-403	76
986	Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. 2008 , 14, 6106-15	59
985	Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. 2008 , 7, 3223-36	24
984	ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. 2008 , 7, 3265-74	64
983	Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death. 2008 , 7, 3816-24	16
982	Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. 2008 , 19, 25-31	30
981	Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41. 2008 , 82, 10032-41	28
980	Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines. 2008 , 54, 166-75	23
979	Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. 2008 , 7, 603-8	49
978	Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines. 2008 , 7, 1104-8	28

977	An investigation on the use of tributyrin nanoemulsions for docetaxel delivery. 2008 , 18, 189-195	3
976	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. 2008 , 93, 57-66	50
975	Phacoemulsification in pseudoexfoliation syndrome. 2008 , 222, 112-6	17
974	Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. 2008 , 14, 3193-203	103
973	Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). 2008 , 7, 1024-32	39
972	GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. 2008 , 14, 5769-77	52
971	IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. 2008 , 68, 8351-60	46
970	Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. 2008 , 14, 7340-7	100
969	A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. 2008 , 105, 13775-80	61
968	Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. 2008 , 68, 3429-39	153
967	Vitamin E analog alpha-TEA, methylseleninic acid, and trans-resveratrol in combination synergistically inhibit human breast cancer cell growth. 2008 , 60, 401-11	10
966	HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. 2008 , 7, 2589-98	92
965	A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. 2008 , 7, 330-40	49
964	Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. 2008 , 49, 1800-9	30
963	Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosourea in camptothecin-resistant cells. 2008 , 74, 517-26	6
962	Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells. 2008 , 7, 1698-707	22
961	Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. 2008 , 7, 1751-61	45
960	Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. 2008 , 100, 580-95	110

959	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. 2008 , 19, 1097-109	38
958	Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). 2008 , 52, 4432-41	163
957	Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. 2008 , 14, 4326-35	26
956	Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter. 2008 , 49, 1480-8	19
955	Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. 2008 , 7, 1080-90	55
954	Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. 2008 , 14, 5090-8	36
953	Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. 2008 , 7, 800-8	58
952	Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. 2008 , 7, 3285-97	89
951	Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. 2008 , 14, 8132-42	77
950	Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. 2008 , 14, 6042-54	198
949	Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. 2008 , 324, 1028-36	42
948	Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. 2008 , 7, 1647-55	64
947	Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. 2008 , 14, 912-23	86
946	Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. 2008 , 82, 6576-84	27
945	Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. 2008 , 68, 5216-25	79
944	Rad9 plays an important role in DNA mismatch repair through physical interaction with MLH1. 2008 , 36, 6406-17	38
943	Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. 2008 , 14, 5416-25	27
942	Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. 2008 , 68, 8004-13	62

941	Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. 2008 , 29, 1893-900	80
940	Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. 2008 , 52, 2111-9	26
939	Cisplatin abrogates the geldanamycin-induced heat shock response. 2008 , 7, 3256-64	50
938	A genomic approach to identify molecular pathways associated with chemotherapy resistance. 2008 , 7, 3141-9	59
937	Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. 2008 , 10, 309-19	29
936	Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. 2008 , 49, 786-97	29
935	The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. 2008 , 49, 1374-83	33
934	Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. 2008 , 16, 252-60	16
933	Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. 2008 , 68, 7638-49	136
932	Anti-tumor activity of phenoxodiol: from bench to clinic. 2008 , 4, 475-82	15
931	CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. 2008 , 6, 246-56	17
930	Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. 2008 , 7, 3408-19	88
929	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. 2008 , 100, 184-98	295
928	Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. 2008 , 24, 1537-44	13
927	Potential of cytotoxicity by combination of imatinib and chlorimipramine in glioma. 2008 ,	3
926	Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA. 2008 , 7, 440-7	18
925	CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. 2008 , 19, 1517-23	14
924	Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. 2008 , 111, 2200-10	78

923	Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. 2008 , 111, 3742-50	110
922	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. 2008 , 111, 1654-64	174
921	Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- κ B pathways in subtypes of diffuse large B-cell lymphoma. 2008 , 111, 3701-13	287
920	BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. 2008 , 111, 2843-53	108
919	Potential of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. 2008 , 111, 3723-34	73
918	mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. 2008 , 112, 2020-3	105
917	Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. 2008 , 112, 5161-70	25
916	Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. 2008 , 112, 1346-56	86
915	High-order combination effects and biological robustness. 2008 , 4, 215	79
914	Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment. 2008 , 14, 1098-112	9
913	Protein kinase C beta in malignant pleural mesothelioma. 2008 , 19, 841-8	9
912	WITHDRAWN: Very strong synergy between modified RANTES and gp41 binding peptides leads to potent anti-HIV-1 activity. 2009 ,	
911	Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. 2008 , 19, 465-75	11
910	Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression. 2008 , 121, 1975-1979	17
909	The Broad Spectrum HDAC Inhibitor PCI-24781 Induces Caspase- and ROS-Dependent Apoptosis and is Synergistic with Bortezomib in Lymphoma. 2008 ,	
908	Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. 2008 , 44, ix-xiv	34
907	Ciglitazone, an agonist of peroxisome proliferator-activated receptor α exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin. 2008 ,	
906	Combining Erlotinib with Cytotoxic Chemotherapy May Overcome Resistance Caused by T790M Mutation of EGFR Gene in Non-Small Cell Lung Carcinoma. 2009 , 8, 92	1

905	Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. 2009 , 34,	3
904	New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses. 2009 , 14, 1927-37	5
903	Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. 2009 , 4, e5223	213
902	Altering chemosensitivity by modulating translation elongation. 2009 , 4, e5428	71
901	Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. 2009 , 36,	
900	Differential effects of several phytochemicals and their derivatives on murine keratinocytes in vitro and in vivo: implications for skin cancer prevention. 2009 , 30, 1008-15	59
899	Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance. 2009 , 69, 8670-7	30
898	Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. 2009 , 284, 17102-17109	30
897	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. 2009 , 53, 1194-203	49
896	Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. 2009 , 331, 327-37	21
895	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. 2009 , 20, 862-7	242
894	The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. 2009 , 8, 930-9	60
893	Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cells. 2009 , 83, 3298-311	24
892	Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. 2009 , 8, 2211-20	45
891	Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. 2009 , 183, 6800-7	28
890	Alpha-tocopheryl succinate potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in human H460 lung cancer cells. 2009 , 41, 737-45	16
889	The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. 2009 , 69, 3021-31	220
888	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. 2009 , 53, 2424-31	30

887	Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. 2009 , 15, 1698-707	53
886	Novel synergistic antibiofilm combinations for salvage of infected catheters. 2009 , 58, 936-944	53
885	Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. 2009 , 15, 5108-16	50
884	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. 2009 , 106, 18351-6	226
883	Correction: Article on Differential Sensitivity to IGF-IR Inhibitor. 2009 , 69, 2149.2-2149	
882	Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. 2009 , 69, 6223-31	118
881	MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. 2009 , 15, 933-42	72
880	Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. 2009 , 15, 1250-8	102
879	Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. 2009 , 15, 907-13	44
878	PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. 2009 , 15, 3354-65	80
877	Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. 2009 , 15, 3716-24	31
876	Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. 2009 , 15, 4077-84	76
875	Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment. 2009 , 15, 4348-55	35
874	In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. 2009 , 15, 4649-64	398
873	Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. 2009 , 8, 521-32	38
872	Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells. 2009 , 7, 1354-66	70
871	Dose and Sample Size Determination for Multi-Drug Combination Studies. 2009 , 1, 301-316	8
870	Quinacrine and a novel apigenin dimer can synergistically increase the pentamidine susceptibility of the protozoan parasite Leishmania. 2009 , 63, 1179-90	23

869	Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. 2009 , 8, 1273-80	24
868	Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. 2009 , 8, 443-53	65
867	The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. 2009 , 8, 2621-30	26
866	Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines. 2009 , 21, 338-46	9
865	A traditional Chinese medicine formulation consisting of Rhizoma Corydalis and Rhizoma Curcumae exerts synergistic anti-tumor activity. 2009 , 22, 1077-83	58
864	Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. 2009 , 8, 808-19	30
863	Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction. 2009 , 1, 4-17	30
862	MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC. 2009 , 8, 522-30	30
861	Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772). 2009 , 9, 595-607	19
860	Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560. 2009 , 20, 47-54	11
859	Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. 2009 , 15, 520-31	25
858	Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. 2009 , 15, 5820-8	29
857	MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. 2009 , 8, 15	1
856	Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. 2009 , 2009, 794901	23
855	Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. 2009 , 16, 401-13	59
854	Combination effects of SC144 and cytotoxic anticancer agents. 2009 , 20, 312-20	10
853	Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. 2009 , 5, e1000674	45
852	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. 2009 , 53, 3715-9	16

851	Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. 2009 , 8, 394-406	104
850	Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. 2009 , 331, 816-26	81
849	Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. 2009 , 7, 890-6	47
848	Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. 2009 , 69, 9330-6	435
847	Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. 2009 , 15, 6367-77	34
846	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. 2009 , 8, 1547-56	25
845	Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. 2009 , 7, 1946-53	41
844	Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. 2009 , 18, 469-79	26
843	Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. 2009 , 15, 5117-25	52
842	ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. 2009 , 75, 1231-9	55
841	BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. 2009 , 8, 3341-9	199
840	Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. 2009 , 15, 6158-66	75
839	The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. 2009 , 15, 6462-71	12
838	Non-competitive androgen receptor inhibition in vitro and in vivo. 2009 , 106, 7233-8	78
837	Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma. 2009 , 15, 1232-40	9
836	The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. 2009 , 8, 2027-35	44
835	Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells. 2009 , 7, 703-12	24
834	BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. 2009 , 15, 150-9	79

833	Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. 2009 , 69, 4235-43	86
832	Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. 2009 , 69, 8620-8	66
831	RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. 2009 , 15, 190-200	11
830	Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. 2009 , 15, 1708-20	34
829	Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains. 2009 , 83, 7862-72	45
828	Potential of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells. 2009 , 41, 1018-26	13
827	Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. 2009 , 69, 565-72	304
826	Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. 2009 , 15, 570-7	89
825	Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux. 2009 , 122, 3330-9	91
824	Delta9-tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro. 2009 , 207, 75-82	39
823	Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay. 2009 , 9, 38	23
822	Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. 2009 , 393, 112-9	19
821	Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. 2009 , 315, 2471-8	12
820	Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562. 1993 , 51, 209-13	12
819	Hydroxyurea enhances 3'-azido-3'-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models. 1994 , 52, 291-5	9
818	In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. 1999 , 62, 143-8	13
817	Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. 2009 , 82, 176-83	25
816	Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. 2009 , 82, 440-9	81

815	Growth inhibitory and differentiation effects of chloroquine and its analogue on human leukemic cells potentiate fetal hemoglobin production by targeting the polyamine pathway. 2009 , 77, 1021-8	12
814	A rice bran polyphenol, cycloartenyl ferulate, elicits apoptosis in human colorectal adenocarcinoma SW480 and sensitizes metastatic SW620 cells to TRAIL-induced apoptosis. 2009 , 77, 1487-96	58
813	G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo. 2009 , 78, 115-22	30
812	Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. 2009 , 78, 1366-73	49
811	Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. 2009 , 81, 82-7	33
810	Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. 2009 , 83, 86-9	15
809	Proteasome proteolytic profile is linked to Bcr-Abl expression. 2009 , 37, 357-66	14
808	Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model. 2009 , 37, 593-603	10
807	Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. 2009 , 15, 429-40	626
806	Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. 2009 , 31, 1263-73	3
805	Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. 2009 , 125, 463-73	61
804	Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. 2009 , 125, 2711-20	10
803	The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. 2009 , 125, 2957-69	34
802	Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. 2010 , 126, 1004-16	35
801	Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. 2010 , 126, 852-63	61
800	Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. 2010 , 126, 1144-54	53
799	Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. 2010 , 127, 1197-208	24
798	Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors. 2009 , 4, 283-90	34

797	Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. 2009 , 115, 3887-96	48
796	In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. 2009 , 81, 211-6	5
795	Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. 2009 , 98, 2540-8	30
794	Myocilin promotes substrate adhesion, spreading and formation of focal contacts in podocytes and mesangial cells. 2009 , 131, 167-80	21
793	Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells. 2009 , 14, 1076-85	11
792	Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. 2009 , 256, 135-40	38
791	Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination. 2009 , 33, 1165-72	6
790	Growth factor receptors signaling in glioblastoma cells: therapeutic implications. 2009 , 92, 137-47	25
789	EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins. 2009 , 95, 175-184	6
788	Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. 2009 , 118, 21-32	28
787	Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. 2009 , 27, 393-401	22
786	The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro. 2009 , 28, 38-45	6
785	Modeling of tumor growth and anticancer effects of combination therapy. 2009 , 36, 179-97	83
784	In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies. 2009 , 26, 193-201	13
783	Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. 2009 , 89, 45-57	27
782	In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay. 2009 , 32, 1737-42	9
781	Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. 2009 , 64, 445-54	22
780	Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines. 2009 , 65, 5-12	15

779	ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress. 2009 , 65, 41-54	28
778	Efficacy of insecticide mixtures against pyrethroid- and organophosphate-resistant populations of <i>Spodoptera litura</i> (Lepidoptera: Noctuidae). 2009 , 65, 266-74	60
777	Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. 2009 , 9, 1952-66	34
776	Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. 2009 , 23, 303-7	30
775	Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205. 2009 , 9, 10	15
774	AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. 2009 , 4, 47	44
773	Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). 2009 , 9, 1	140
772	Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. 2009 , 100, 546-51	68
771	Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. 2009 , 100, 2459-64	55
770	The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. 2009 , 144, 358-66	28
769	Analysis of Aurora B kinase in non-Hodgkin lymphoma. 2009 , 89, 1364-73	34
768	Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. 2009 , 23, 961-70	63
767	Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. 2009 , 23, 1755-62	34
766	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. 2009 , 23, 2265-74	51
765	Synergistic drug combinations tend to improve therapeutically relevant selectivity. 2009 , 27, 659-66	650
764	The combination of baicalin and baicalein enhances apoptosis via the ERK/p38 MAPK pathway in human breast cancer cells. 2009 , 30, 1648-58	82
763	Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. 2009 , 30, 617-27	22
762	Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. 2009 , 16, 551-60	28

761	Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. 2009 , 100, 649-55	14
760	Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy. 2009 , 100, 1889-95	36
759	Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. 2009 , 101, 1307-15	32
758	Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. 2009 , 104, 107-14	15
757	Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. 2009 , 103, 1729-37	20
756	Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. 2009 , 158, 610-20	75
755	Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. 2009 , 29, 670-7	32
754	Down-regulation of lipocalin 2 contributes to chemoresistance in glioblastoma cells. 2009 , 111, 1238-51	25
753	Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. 2009 , 33, 100-8	19
752	In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. 2009 , 33, 129-39	251
751	Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib. 2009 , 33, 686-92	7
750	JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). 2009 , 33, 1525-9	26
749	Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents. 2009 , 33, 937-47	9
748	Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. 2009 , 33, 239-46	34
747	Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. 2009 , 30, 3614-25	125
746	Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker. 2009 , 17, 1264-75	24
745	Synthesis, cytotoxic and combined cDDP activity of new stable curcumin derivatives. 2009 , 17, 3043-52	65
744	Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes. 2009 , 17, 5614-26	44

743	Preparation and evaluation of self-nanoemulsifying tablets of carvedilol. 2009 , 10, 183-92	73
742	AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. 2009 , 4, 199-208	39
741	Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. 2009 , 69, 3842-9	112
740	Enhancing prostate cancer cryotherapy using tumour necrosis factor related apoptosis-inducing ligand (TRAIL) sensitisation in an in vitro cryotherapy model. 2009 , 59, 207-13	10
739	FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. 2009 , 12, 81-9	83
738	Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. 2009 , 45, 890-8	33
737	Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. 2009 , 45, 1855-64	36
736	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. 2017 , 8, 23061-23072	10
735	A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. 2014 , 5, 375-85	58
734	Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. 2014 , 5, 298-308	41
733	MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas. 2017 , 8, 53968-53977	25
732	Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. 2014 , 5, 4071-86	21
731	Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. 2017 , 8, 41091-41101	12
730	Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. 2014 , 5, 2372-89	55
729	Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells. 2017 , 8, 39460-39475	7
728	CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia. 2017 , 8, 42571-42587	31
727	Liposomal co-delivered oleanolic acid attenuates doxorubicin-induced multi-organ toxicity in hepatocellular carcinoma. 2017 , 8, 47136-47153	22
726	CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4. 2017 , 8, 65143-65151	29

725	Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. 2014 , 5, 1198-211	18
724	STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. 2014 , 5, 2529-41	52
723	Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. 2017 , 8, 73947-73963	19
722	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. 2017 , 8, 71981-71995	14
721	Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells. 2017 , 8, 76085-76098	11
720	Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors. 2017 , 8, 84986-84995	22
719	The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. 2017 , 8, 67709-67722	12
718	Combinatorial inhibition of Plk1 and PKC δ in cancer cells with different p53 status. 2014 , 5, 2263-75	9
717	Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. 2017 , 8, 50376-50392	23
716	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. 2017 , 8, 52026-52044	17
715	Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. 2014 , 5, 2807-19	29
714	A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. 2017 , 8, 85120-85135	11
713	Cell cycle specific radiosensitisation by the disulfiram and copper complex. 2017 , 8, 65900-65916	15
712	The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. 2017 , 8, 95116-95134	19
711	Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells. 2014 , 5, 4765-78	35
710	Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. 2014 , 5, 4347-60	19
709	A novel copper(I) complex induces ER-stress-mediated apoptosis and sensitizes B-acute lymphoblastic leukemia cells to chemotherapeutic agents. 2014 , 5, 5978-91	21
708	Combination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells. 2017 , 8, 72727-72738	5

707	Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer. 2017 , 8, 77181-77194	15
706	IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines. 2017 , 8, 103465-103476	18
705	Cyclooxygenase-2 mediated synergistic effect of ursolic acid in combination with paclitaxel against human gastric carcinoma. 2017 , 8, 92770-92777	13
704	Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway. 2017 , 8, 103710-103730	15
703	Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism. 2017 , 8, 103952-103967	5
702	Microtubins: a novel class of small synthetic microtubule targeting drugs that inhibit cancer cell proliferation. 2017 , 8, 104007-104021	6
701	Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases. 2017 , 8, 103797-103814	10
700	Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells. 2017 , 8, 105047-105060	5
699	Combined venetoclax and alvocidib in acute myeloid leukemia. 2017 , 8, 107206-107222	46
698	Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis. 2017 , 8, 110133-110144	15
697	Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals. 2017 , 8, 111144-111160	19
696	Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells. 2017 , 8, 112942-112958	16
695	FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. 2018 , 9, 8870-8886	18
694	Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. 2014 , 5, 7065-80	22
693	Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. 2014 , 5, 7805-19	20
692	Therapeutic potential of ERK5 targeting in triple negative breast cancer. 2014 , 5, 11308-18	35
691	The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. 2018 , 9, 3815-3829	16
690	Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells. 2014 , 5, 8637-50	35

- 689 Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. **2014**, 5, 8737-49 65
- 688 Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines. **2018**, 9, 18254-18268 14
- 687 Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma. **2018**, 9, 21086-21099 4
- 686 EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. **2018**, 9, 21930-21942 21
- 685 CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. **2018**, 9, 26032-26045 16
- 684 Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. **2018**, 9, 26491-26506 13
- 683 Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. **2018**, 9, 26834-26851 11
- 682 ER β -mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. **2018**, 9, 27736-27751 7
- 681 A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. **2018**, 9, 29680-29697 11
- 680 LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL). **2018**, 9, 31832-31841 6
- 679 MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors. **2014**, 5, 11723-36 17
- 678 A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells. **2018**, 9, 34379-34397 8
- 677 Staurosporine, an inhibitor of hormonally up-regulated neu-associated kinase. **2018**, 9, 35962-35973 6
- 676 Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment. **2018**, 9, 37319-37332 11
- 675 AMPK activation by AICAR sensitizes prostate cancer cells to radiotherapy. **2019**, 10, 749-759 11
- 674 Targeted drug combination therapy design based on driver genes. **2019**, 10, 5255-5266 7
- 673 TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. **2019**, 10, 5011-5019 3
- 672 deletion drives acute myeloid leukemia resistance to MEK inhibitors. **2019**, 10, 5755-5767 5

671	Targeting PI3K alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. 2020 , 11, 969-981	9
670	The cytotoxicity of gallium maltolate in glioblastoma cells is enhanced by metformin through combined action on mitochondrial complex 1. 2020 , 11, 1531-1544	4
669	Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. 2015 , 6, 27332-42	12
668	Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells. 2015 , 6, 4159-70	41
667	Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. 2015 , 6, 2009-22	40
666	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. 2015 , 6, 5118-33	30
665	Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). 2015 , 6, 1954-66	24
664	The heparan sulfate mimetic PG545 interferes with Wnt/ β -catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. 2015 , 6, 4992-5004	37
663	FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. 2015 , 6, 9189-205	44
662	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. 2015 , 6, 10399-414	29
661	Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. 2011 , 2, 797-809	154
660	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. 2015 , 6, 9086-98	31
659	Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. 2015 , 6, 14926-39	38
658	Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. 2015 , 6, 13119-32	33
657	Thyocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. 2011 , 2, 1109-26	66
656	PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. 2011 , 2, 1134-44	35
655	Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. 2015 , 6, 16623-37	40
654	Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells. 2015 , 6, 22624-40	21

- 653 Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization. **2015**, 6, 17328-41 49
- 652 Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. **2015**, 6, 21507-21 60
- 651 Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. **2015**, 6, 23807-19 3
- 650 Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. **2015**, 6, 26090-103 30
- 649 Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways. **2015**, 6, 26252-65 9
- 648 By activating Fas/ceramide synthase 6/p38 kinase in lipid rafts, stichoposide D inhibits growth of leukemia xenografts. **2015**, 6, 27596-612 19
- 647 AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. **2015**, 6, 28001-10 30
- 646 The Hsp90 inhibitor NVP-AUY922-AG inhibits NF- κ B signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. **2012**, 3, 525-34 35
- 645 Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. **2015**, 6, 30149-64 36
- 644 Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer. **2015**, 6, 30773-86 9
- 643 HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. **2015**, 6, 32075-88 20
- 642 Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine. **2015**, 6, 32790-804 52
- 641 Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. **2011**, 2, 1155-1164 22
- 640 Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. **2015**, 6, 41123-33 3
- 639 Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. **2015**, 6, 30487-99 28
- 638 Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. **2015**, 6, 32856-67 15
- 637 The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. **2015**, 6, 37930-47 26
- 636 Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3K/Br PKC signaling pathways. **2015**, 6, 44832-48 12

635	Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. 2016 , 7, 402-17	17
634	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-B. 2016 , 7, 1323-40	30
633	Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. 2015 , 6, 41535-49	17
632	Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. 2016 , 7, 2796-808	49
631	Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. 2016 , 7, 8105-18	16
630	Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BE235 and pan-histone deacetylase inhibitor against human pancreatic cancer. 2012 , 3, 1416-27	40
629	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. 2016 , 7, 21496-509	18
628	Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. 2016 , 7, 18965-77	20
627	Adaptive metabolic rewiring to chronic SFK inhibition. 2017 , 8, 66758-66768	3
626	Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer. 2016 , 7, 23933-46	33
625	Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer. 2016 , 7, 29187-98	3
624	Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma. 2016 , 7, 36235-36246	10
623	High throughput chemical library screening identifies a novel p110- β inhibitor that potentiates the anti-myeloma effect of bortezomib. 2016 , 7, 38523-38538	4
622	The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo. 2016 , 7, 45500-45512	1
621	Single Agent and Synergistic Activity of Maritoclax with ABT-263 in Nasopharyngeal Carcinoma (NPC) Cell Lines. 2020 , 31, 1-13	2
620	Translational and HIF1-Dependent Metabolic Reprogramming Underpin Oncometabolome Plasticity and Synergy Between Oncogenic Kinase Inhibitors and Biguanides.	1
619	Drugs in a Curative Combination Therapy for Lymphoma Exhibit Low Cross-Resistance But Not Pharmacological Synergy.	3
618	Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles. 2019 , 14, 9199-9216	37

617	MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. 2013 , 20, 2486-99	20
616	P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer. 2014 , 21, 501-10	28
615	Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer. 2019 , 16, 829-838	7
614	Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships. 2017 , 17, 735-755	1
613	Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. 2020 , 20, 433-457	17
612	Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application. 2020 , 18, 153-166	2
611	Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells. 2017 , 17, 301-308	29
610	Liposomes Co- encapsulating Anticancer Drugs in Synergistic Ratios as an Approach to Promote Increased Efficacy and Greater Safety. 2019 , 19, 17-28	9
609	Adenosine Analogues as Opposite Modulators of the Cisplatin Resistance of Ovarian Cancer Cells. 2019 , 19, 473-486	4
608	Synergistic Effect of Novel EGFR Inhibitor AZD8931 and p38 β siRNA in Lung Adenocarcinoma Cancer Cells. 2019 , 19, 638-644	6
607	Synergistic Effect of Bosonine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells. 2019 , 19, 2197-2210	7
606	Dose and Sequence Dependent Synergism from the Combination of Oxaliplatin with Emetine and Patulin Against Colorectal Cancer. 2020 , 20, 264-273	6
605	Nanomedicine-Mediated Combination Drug Therapy in Tumor. 2017 , 4, 1-10	2
604	Up-Regulation of MiRNA-125a-5p Inhibits Cell Proliferation and Increases EGFR-TKI Induced Apoptosis in Lung Cancer Cells. 2019 , 20, 3361-3367	9
603	Thymoquinone Augments Cyclophosphamide-Mediated Inhibition of Cell Proliferation in Breast Cancer Cells. 2019 , 20, 1153-1160	15
602	Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib. 2019 , 20, 2781-2787	9
601	Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737. 2020 , 21, 675-681	5
600	MiRNA-7 Replacement Effect on Proliferation and Tarceva-Sensitivity in U373-MG Cell Line. 2020 , 21, 1747-1753	4

599	Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. 2020 , Online ahead of print,	9
598	Identification of Compounds With Glucocorticoid Sparing Effects on Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-Like Synoviocytes. 2020 , 11, 607713	2
597	Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models. 2020 , 12,	1
596	Combined inhibition of NF-B and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells. 2013 , 21, 173-80	5
595	Synergistic effects of ethyl acetate fraction of Ficus septica Burm. f. and doxorubicin chemotherapy on T47D human breast cancer cell line. 2012 , 10, 1162-70	2
594	Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. 2007 , 13, 1534-40	32
593	Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. 2012 , 18, 2383-9	42
592	Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. 2020 , 26, 598-613	9
591	Interaction between cisplatin, 5-fluorouracil and vincristine on human hepatoma cell line (7721). 1998 , 4, 418-420	10
590	Preclinical Assays for Identifying Cancer Chemopreventive Phytochemicals. 2009 , 2009, 1-15	2
589	Expression profile-driven discovery of AURKA as a treatment target for liposarcoma. 2019 , 55, 938-948	6
588	The HSP90 inhibitor onalespib potentiates 177Lu-DOTATATE therapy in neuroendocrine tumor cells. 2019 , 55, 1287-1295	10
587	Cellular and molecular alterations induced by low-dose fisetin in human chronic myeloid leukemia cells. 2019 , 55, 1261-1274	1
586	Triptolide inhibits epithelial-mesenchymal transition and induces apoptosis in gefitinib-resistant lung cancer cells. 2020 , 43, 1569-1579	8
585	Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells. 2016 , 31, 357-66	5
584	Synergistic inhibitory effect of wogonin and low-dose paclitaxel on gastric cancer cells and tumor xenografts. 2013 , 25, 505-13	9
583	Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells. 2015 , 7, 400-6	16
582	Combinatorial Antitumor Activity of Oxaliplatin with Epigenetic Modifying Agents, 5-Aza-CdR and FK228, in Human Gastric Cancer Cells. 2018 , 26, 591-598	2

581	Catalpol and Mannitol, Two Components of , Exhibit Anticonvulsant Effects Probably via GABA Receptor Regulation. 2020 , 28, 137-144	3
580	Drug interaction: focusing on response surface models. 2010 , 58, 421-34	25
579	Digitoxin activates EGR1 and synergizes with paclitaxel on human breast cancer cells. 2010 , 9, 10	18
578	Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines. 2017 , 12, 517-525	18
577	Herbal Medicines Showing Synergistic Effects with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) against A549 TRAIL-resistant Lung Cancer Cells: A Screening Study. 2018 , 14, 145-148	6
576	Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. 2016 , 48, 355-64	4
575	<i>In Vitro&/i> Characterization of Docetaxel as a Radiosensitizer in Canine and Feline Cancer Cell Lines. 2012 , 02, 285-292	2
574	Hepatitis C virus inhibitor synergism suggests multistep interactions between heat-shock protein 90 and hepatitis C virus replication. 2016 , 8, 282-90	1
573	Cytotoxic Effects of Some Flavonoids and Imatinib on the K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index Method. 2019 , 36, 96-105	6
572	R-(-)-carvone Attenuated Doxorubicin Induced Cardiotoxicity and Potentiated Its Anticancer Toxicity. 2020 , 37, 98-103	10
571	Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. 2016 , 7, 425-432	4
570	Cytotoxicity enhancement in MDA-MB-231 cells by the combination treatment of tetrahydropalmatine and berberine derived from Corydalis yanhusuo W. T. Wang. 2014 , 3, 68-72	35
569	Resveratrol enhances cisplatin-induced apoptosis in human hepatoma cells via glutamine metabolism inhibition. 2018 , 51, 474-479	22
568	Combinational Use of Phytochemicals and Chemotherapeutic Drugs Enhance Their Therapeutic Potential on Human Cervical Cancer Cells. 2019 , 12,	5
567	Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells. 2012 , 13, 5903-8	12
566	siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. 2013 , 14, 7719-24	38
565	Genistein reinforces the inhibitory effect of Cisplatin on liver cancer recurrence and metastasis after curative hepatectomy. 2013 , 14, 759-64	16
564	In vitro and in vivo antitumor activity of tiliacorinine in human cholangiocarcinoma. 2014 , 15, 7473-8	6

563	Down-regulation of Mcl-1 by small interference RNA induces apoptosis and sensitizes HL-60 leukemia cells to etoposide. 2014 , 15, 629-35	16
562	Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells. 2014 , 15, 9939-43	11
561	Ethanol extract from <i>Derris scandens</i> Benth mediates radiosensitization via two distinct modes of cell death in human colon cancer HT-29 cells. 2014 , 15, 1871-7	13
560	Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells. 2015 , 16, 5191-7	27
559	Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. 2017 , 6,	92
558	R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. 2019 , 8,	17
557	The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies. 2020 , 9,	13
556	. 2020 , 34,	2
555	The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells. 2016 , 4, e2168	7
554	Ecotoxicity of disinfectant benzalkonium chloride and its mixture with antineoplastic drug 5-fluorouracil towards alga. 2018 , 6, e4986	14
553	Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of Seliciclib. 2013 , 7, 4	9
552	Oxyresveratrol modulates the immune response in vitro. 2021 , 32, 70-78	1
551	Induction of apoptosis in human hormone-refractory prostate cancer cell lines by using resveratrol in combination with AT-101. 2021 , e14267	
550	Curcumin Synergistically Enhances the Cytotoxicity of Arsenic Trioxide in U266 Cells by Increasing Arsenic Uptake. 2021 , 2021, 3083041	0
549	Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro. 2021 , 13,	5
548	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. 2021 , 12, e0247321	11
547	KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri. 2021 , 26, 897-907	
546	Inhibitor Combinations Reveal Wiring of the Proteostasis Network in Prostate Cancer Cells. 2021 , 64, 14809-14821	

545	PLC β /PKC δ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development And Progression. 2021 ,	0
544	Dalpiciclib and Pyrotinib Exert Synergistic Antitumor Effects in Triple Positive Breast Cancer.	
543	Delineating the Switch between Senescence and Apoptosis in Cervical Cancer Cells under Ciclopirox Treatment. 2021 , 13,	0
542	Combination Effects of Polyphenols Present in Sugarcane on Proliferation in MCF-7 Human Breast Cancer Cells. 1	1
541	Cytotoxic and antitumoral activity of N-(9H-purin-6-yl) benzamide derivatives and related water-soluble prodrugs. 2021 ,	1
540	Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple Negative Breast Cancer.	
539	Redox-Modulating Capacity and Antineoplastic Activity of Wastewater Obtained from the Distillation of the Essential Oils of Four Bulgarian Oil-Bearing Roses. 2021 , 10,	0
538	Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis. 2021 , 12, 6060	2
537	CLIP-170S is a microtubule β -TIP variant that confers resistance to taxanes by impairing drug-target engagement. 2021 , 56, 3264-3275.e7	0
536	Inactivation of SARS Coronavirus 2 and COVID-19 patient samples for contemporary immunology and metabolomics studies.	0
535	Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma. 2021 , 13,	0
534	CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts.	0
533	Synergistic in-vitro antiviral effects of combination treatment using anidulafungin and T-1105 against Zika virus infection. 2021 , 195, 105188	2
532	Sub-lethal effects of soil multiple contamination on the avoidance behaviour of <i>Eisenia fetida</i> . 2021 , 226, 112861	0
531	Combination of multifunctional ursolic acid with kinase inhibitors for anti-cancer drug carrier vesicles. 2021 , 131, 112481	0
530	Prädiktive in vitro-Testung von neuen Zytostatika und Resistenzmodulatoren. 2000 , 185-192	
529	Interactions.	
528	Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells. 2001 , 165, 2082-5	5

- 527 L-Canavanine as a radiosensitization agent for human pancreatic cancer cells. **2003**, 37-43
- 526 The basic principles for combination therapy. **2004**, 41-51 1
- 525 Evaluation of Twenty Human Adenoviral Types and One Infectivity-Enhanced Adenovirus for the Therapy of Soft Tissue Sarcoma. **2006**, 061222090124001
- 524 Evaluation of Twenty Human Adenoviral Types and One Infectivity-Enhanced Adenovirus for the Therapy of Soft tissue Sarcoma. **2006**, 061221065408001
- 523 Anti-proliferative Effect of Tetra-arsenic Oxide (TetraAs₄O₁₁) in Human Gastric Cancer Cells in Vitro. **2007**, 37, 305-309
- 522 Antitumor Activity of LB42907, a Potent and Selective Farnesyltransferase Inhibitor: Synergistic Effect in Combination with Other Anticancer Drugs. **2008**, 29, 1303-1310
- 521 Mixtures. **2009**, 307-311
- 520 In Vitro Performance and Analysis of Combination Anti-infective Evaluations. **2009**, 1135-1149
- 519 Applying Emax model and bivariate thin plate splines to assess drug interactions. **2010**, 2, 279-92 2
- 518 Preclinical Evaluation. **2011**, 39-60 1
- 517 Nanoscale Delivery Systems for Combination Chemotherapy. 1013-1050 1
- 516 Effect of staurosporine and ucn-01 on gemcitabine cytotoxicity in relation to cell cycle effects and p53 status. **2012**, 1, 29
- 515 5-androstene 3 α ,7 β -diol induces autophagic cell death of human breast cancer cells and enhances radiation cytotoxicity. **2012**, 1, 25 0
- 514 Base Excision Repair Inhibition by Methoxyamine Impairs Growth and Sensitizes Osteosarcoma Cells to Conventional Treatments. **2014**, 05, 307-314
- 513 Nuclear Components and Plasma Membrane as Targets of Chemotherapeutic Agents. **1989**, 120-127
- 512 Advances in the Treatment of HIV-1 Infections. **1991**, 217-236
- 511 COMBO: New Concepts and Methods for Designing and Analyzing Experiments on Combination Therapy. **1992**, 29-38
- 510 Prätherapeutische in-vitro-Chemosensitivität bei gynäkologischen Tumoren. Einsatz des ATP-CSA (ATP-Chemo-Sensitivitäts-Assay). **1993**, 1074-1076

- 509 Effects on Ara-C Cytotoxicity for AML Colony Forming Cells By Priming With rhGM-CSF and rhIL-3 In Vitro and In Vivo. **1994**, 181-184
- 508 Synergistic cytotoxicity as an endpoint for the development of rational chemotherapeutic. Drug combinations. **1994**, 798-803
- 507 Incorporating Assessments of Sequence-Dependence in Developmental Studies of Combination Chemotherapy Regimens Containing New Agents and Platinum Compounds. **1996**, 205-220
- 506 Studies on cisplatin plus 5 -fluorouracil chemotherapy for the head and neck squamous cell carcinoma using multicellular tumor spheroids. **1996**, 42, 207-216
- 505 GM-CSF Dose Response Curves in Priming of AML Progenitors for Ara-C. **1997**, 193-196
- 504 Different Potential of G-CSF, GM-CSF, and pIXY in Priming of Myeloid Leukemic Progenitors for Ara-C. **1997**, 197-201
- 503 Standardized peripheral blood mononuclear cell culture assay for zidovudine susceptibility testing of clinical human immunodeficiency virus type 1 isolates: effect of reducing the numbers of replicates and concentrations. **1997**, 35, 756-8 1
- 502 Primary Resistance to Ara-C in AML Progenitor Cells and its Modulation by Cytokines. **1998**, 651-654
- 501 Enhanced Effects of Adriamycin by Combination with a New Ribonucleotide Reductase Inhibitor, Trimidox, in Murine Leukemia. **1998**, 556-561
- 500 Animal Models for Varicella-zoster Infections. **1999**, 963-VIII
- 499 HIV Transmission Models: Lessons Learned for Microbicide Formulation Design. **2014**, 55-89
- 498 *Cissus quadrangularis* Linn. Stem Ethanolic Extract Liberates Reactive Oxygen Species and Induces Mitochondria Mediated Apoptosis in KB Cells. **2015**, 11, S365-74 2
- 497 Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition. **2015**, 6, 25801-14 2
- 496 Assessment of Drug Interactions with Repeated Measurements. **2017**, 277-291
- 495 In Vitro Performance and Analysis of Combination Anti-infective Evaluations. **2017**, 1329-1345 1
- 494 Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer.
- 493 Translational and HIF1 α dependent metabolic reprogramming underpin oncometabolome plasticity and synergy between oncogenic kinase inhibitors and biguanides.
- 492 Additive Dose Response Models: Explicit Formulations and the Loewe Additivity Consistency Condition.

- 491 Ovarian carcinoma glyco-antigen targeted by human IgM antibody. **2017**, 12, e0187222 0
- 490 Developing a genetic signature to predict drug response in ovarian cancer. **2018**, 9, 14828-14848 3
- 489 Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia.
- 488 Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R inhibitors.
- 487 OVER KANSERİN EYELİK FOTODİYAMİK TERAPİ İLE KOMBİNASYON TERAPİ UYGULAMASI. **2018**, 49,
- 486 Dual BRD4 and AURKA Inhibition is Synergistic against MYCN-amplified and nonamplified Neuroblastoma.
- 485 Nitron-Trolox conjugate as an inhibitor of lipid oxidation: Towards synergistic antioxidant effects.
- 484 Comparison of null models for combination drug therapy reveals Hand model as biochemically most plausible.
- 483 Novel Poly (ADP-Ribose) Polymerase Inhibitor AZD2461 Combined with Valproic Acid Exerts Mild Antagonistic Effects in Hela Cells. **2018**, In Press,
- 482 Luminescent Microbial Bioassays and Microalgal Biosensors as Tools for Environmental Toxicity Evaluation. **2019**, 1-58
- 481 <i>in Vitro&/i> Hippocampal Electrophysiology and <i>in Vivo&/i> Quantitative EEG Revealed Robust Neurophysiological Effects of the Antivertigo-Agent Vertigoheel&sup® in a Rat Study. **2019**, 10, 407-425 0
- 480 Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases.
- 479 Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069. 1
- 478 METFORMIN AND DICHOLOROACETATE COMBINATION EXERT A SYNERGISTIC EFFECT ON CELL VIABILITY OF ORAL SQUAMOUS CELL CARCINOMA. 1
- 477 THE ROLE OF EPITHELIAL-TO-MESENCHYMAL TRANSITION AND AUTOPHAGY IN ANTITUMORAL RESPONSE OF MELANOMA CELL LINES TO TARGET INHIBITION OF MEK AND mTOR KINASES. **2019**, 18, 54-63
- 476 A Consensus Framework Unifies Multi-Drug Synergy Metrics. 1
- 475 Interaction of polyaromatic hydrocarbons and metals on bioaccessibility and toxicity of arsenic. **2019**, 379-380
- 474 The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound.. **2019**, 8, 1224-1232 0

- 473 Phenotype-Based Probabilistic Analysis of Heterogeneous Responses to Cancer Drugs and Their Combination Efficacy. 0
- 472 The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies.
- 471 Imatinib overrides taxane resistance by selective inhibition of novel CLIP1 variant obstructing the microtubule pore. 0
- 470 Toxicity of essential oils: A brief overview of bioassays. **2020**, 9, 71-78
- 469 Cyclic pentapeptide cRGDFk enhances the inhibitory effect of sunitinib on TGF- β -induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells.
- 468 Nitric Oxide inhibits NF- κ B-mediated survival signaling: possible role for anti-TNF- family cancer therapies (Preprint).
- 467 MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer.
- 466 Nitric Oxide inhibits NF- κ B-mediated survival signaling: possible role in overcoming TRAIL resistance (Preprint).
- 465 Modelling bioactivities of combinations of whole extracts of edibles with a simplified theoretical framework reveals the statistical role of molecular diversity and system complexity in their mode of action and their nearly certain safety. **2020**, 15, e0239841
- 464 Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen. **2021**, 1
- 463 Combination of the Glutamyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain A β Pathology in Transgenic Mice. **2021**, 22, 1
- 462 EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. **2021**, 11, 21396 4
- 461 Antibiotic inhibition of the Plasmodium apicoplast decreases haemoglobin degradation and antagonises dihydroartemisinin action. 0
- 460 Modelling bioactivities of combinations of whole extracts of edibles with a simplified theoretical framework reveals the statistical role of molecular diversity and system complexity in their mode of action and their nearly certain safety.
- 459 Chemical mixtures: toxicologic interactions and risk assessment. **2020**, 401-414
- 458 Anti-Proliferative Effect of L. Extract in Human T-Cell Acute Lymphocytic Leukemia Cells. **2020**, 26, 1
- 457 Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway.
- 456 Potentiation of the Effect of Lonidamine by Quercetin in MCF-7 human breast cancer cells through downregulation of MMP-2/9 mRNA Expression. **2020**, 92, e20200548 5

455	Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.	
454	Diosmin in combination with naringenin enhances apoptosis in colon cancer cells. 2022 , 47,	2
453	Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells. 2022 , 47,	0
452	AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill -ITD acute myeloid leukemia. 2021 ,	2
451	6-Thioguanine Inhibits Herpes Simplex Virus 1 Infection of Eyes. 2021 , e0064621	1
450	Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. 2021 ,	4
449	Punicalagin, a pomegranate compound, induces apoptosis and autophagy in acute leukemia. 2021 , 9, e12303	2
448	Identification of clinical combination therapies to induce durable responses in kidney cancers.	
447	The CoREST Repressor Complex Mediates Phenotype Switching and Therapy Resistance in Melanoma.	
446	A Laboratory Study of the Toxicity of Indoxacarb Mixtures against <i>Spodoptera littoralis</i> (Boisd.) (Lepidoptera: Noctuidae). 2020 , 28,	2
445	BRD4-mediated repression of p53 is a target for combination therapy in AML.	
444	Reanalysis of in vivo drug synergy validation study rules out synergy in most cases.	
443	New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy. 2020 , 12, e12391	5
442	The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro. 2020 , 18, 332-341	0
441	The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. 2011 , 1, 925-54	20
440	Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. 2011 , 2, 1155-64	16
439	Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma. 2013 , 3, 390-401	3
438	Chemotherapeutic activities of Carthami Flos and its reversal effect on multidrug resistance in cancer cells. 2013 , 10, 36-40	1

- 437 ABT-737, Synergistically Enhances Daunorubicin-Mediated Apoptosis in Acute Myeloid Leukemia Cell Lines. **2014**, 4, 185-9 5
- 436 Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma. **2015**, 8, 2823-8 7
- 435 Synergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo. **2015**, 5, 2516-30 7
- 434 Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor. **2016**, 80, 21-31 7
- 433 Ambiguine I Isonitrile from Induces Caspase-Independent Cell Death in MCF-7 Hormone Dependent Breast Cancer Cells. **2015**, 49, 1655-1662 7
- 432 Synergistic combination of microtubule targeting anticancer fludelsonone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. **2016**, 6, 97-104 49
- 431 Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells. **2017**, 17, 48-56 4
- 430 Volasertib suppresses the growth of human hepatocellular carcinoma and. **2016**, 6, 2476-2488 13
- 429 The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. **2016**, 6, 2489-2501 21
- 428 A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. **2017**, 7, 657-672 3
- 427 Molecular mechanism underlying the pharmacological interactions of the protein kinase C- α inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells. **2017**, 7, 816-830 2
- 426 Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer. **2017**, 9, 1667-1679 8
- 425 A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells. **2016**, 36, 49-60 33
- 424 Caragaphenol a induces reactive oxygen species related apoptosis in human gastric cancer cells. **2017**, 9, 3804-3815 3
- 423 YM155 enhances docetaxel efficacy in ovarian cancer. **2018**, 10, 696-708 6
- 422 Synergistic Effect of Forbesione From *Garcinia hanburyi* in Combination with 5-Fluorouracil on Cholangiocarcinoma. **2017**, 18, 3343-3351 5
- 421 Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition. **2018**, 8, 2267-2283 4
- 420 Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells. **2019**, 83, 3-10 3

4 ¹⁹	Combined inhibition of FGFR and mTOR pathways is effective in suppressing ovarian cancer. 2019 , 11, 1616-1625	12
4 ¹⁸	Synergistic activity of magnolin combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma cells via targeting PI3K-AKT/mTOR and ERK MAPK pathway. 2019 , 11, 3816-3824	4
4 ¹⁷	Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid. 2019 , 18, 485-498	2
4 ¹⁶	Combined effects of EGFR and hedgehog signaling blockade on inhibition of head and neck squamous cell carcinoma. 2017 , 10, 9816-9828	
4 ¹⁵	Current Methods for Quantifying Drug Synergism. 2019 , 1, 43-48	2
4 ¹⁴	Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. 2020 , 10, 648-661	15
4 ¹³	Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas. 2020 , 10, 856-869	1
4 ¹²	BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K. 2020 , 10, 1900-1918	2
4 ¹¹	Fabrication of Paclitaxel and 17AAG-loaded Poly-ε-Caprolactone Nanoparticles for Breast Cancer Treatment. 2021 , 10,	
4 ¹⁰	Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing. 2021 , 11, 3240-3251	
4 ⁰⁹	Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing -compound mutations. 2021 , 11, 4470-4484	1
4 ⁰⁸	Combination of the 6-thioguanine and disulfiram/Cu synergistically inhibits proliferation of triple-negative breast cancer cells by enhancing DNA damage and disrupting DNA damage checkpoint. 2021 , 1869, 119169	0
4 ⁰⁷	Robust and Efficient Assessment of Potency (REAP): A Quantitative Tool for Dose-response Curve Estimation.	
4 ⁰⁶	Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells. 2021 , 11, 10526	
4 ⁰⁵	The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. 2021 , 9, 1413-1424	2
4 ⁰⁴	Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity. 2021 , 22,	2
4 ⁰³	Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma. 2021 ,	0
4 ⁰²	ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. 2021 , 12, 6813	0

401	Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma. 2021 , 13,	2
400	mTOR Inhibition Overcomes RSK3-mediated Resistance to BET Inhibitors in Small Cell Lung Cancer.	0
399	Polymeric complex based on poly (styrene-alt-maleic anhydride)- targeted with folic acid for doxorubicin delivery to HT-29 colorectal cancer cells. 1-13	
398	The individual and combined effects of ochratoxin A with citrinin and their metabolites (ochratoxin B, ochratoxin C, and dihydrocitrinone) on 2D/3D cell cultures, and zebrafish embryo models. 2021 , 158, 112674	0
397	The agonistic bioanalytical equivalent concentration: A novel tool for assessing the endocrine activity of environmental mixtures. 2021 , 89, 103781	
396	17βEstradiol and Progesterone Role on Glutamate Decarboxylase Activity in Brain Regions Sleeping-Process Related.	
395	In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin. 2021 , 35, 1613-1622	0
394	High-Throughput 3D Tumor Spheroid Array Platform for Evaluating Sensitivity of Proton-Drug Combinations.. 2022 , 23,	0
393	Stimulus [Response mechanistic modeling of pharmacodynamic drug-drug interaction: Extension of the operational receptor model of agonism. 2022 , 28, 100813	
392	Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.. 2021 , 24, 63-75	1
391	Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.. 2022 , 529, 153-167	1
390	All-in-one hollow nanoformulations enabled imaging-guided Mn-amplified chemophototherapy against hepatocellular carcinoma. 2022 , 43, 101382	0
389	Synergy across the drugs approved for the treatment of asthma. 2021 ,	0
388	Prediction of the impact induced by Cd in binary interactions with other divalent metals on wild-type and Cd-resistant strains of <i>Dictyosphaerium chlorelloides</i> . 2021 ,	0
387	Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer.. 2022 , 13, 100189	1
386	PaDef (var. <i>drymifolia</i>), a Plant Antimicrobial Peptide, Triggers Apoptosis, and Induces Global Epigenetic Modifications on Histone 3 in an Acute Lymphoid Leukemia Cell Line.. 2022 , 9, 801816	0
385	Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.. 2022 , 20, 4	
384	Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax.. 2022 ,	1

383	Non-parametric synergy modeling of chemical compounds with Gaussian processes.. 2022 , 23, 14	1
382	The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation.. 2022 , 14,	1
381	Targeted liposomal doxorubicin/ceramides combinations: the importance to assess the nature of drug interaction beyond bulk tumor cells.. 2022 , 172, 61-61	0
380	Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.. 2022 , 12, 23	0
379	A high-throughput approach to identify reproductive toxicants among environmental chemicals using an in vivo evaluation of gametogenesis in budding yeast <i>Saccharomyces cerevisiae</i> .	
378	Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers.. 2022 , 29, 342-350	6
377	Pulmonary Delivery of Theranostic Nanoclusters for Lung Cancer Ferroptosis with Enhanced Chemodynamic/Radiation Synergistic Therapy.. 2022 ,	5
376	Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma.. 2021 , 11, 773186	2
375	A comparison of different regression models for the quantitative analysis of the combined effect of P2Y and P2Y receptor antagonists on ADP-induced platelet activation.. 2022 , 211, 88-97	0
374	Gemcitabine and XCT790, an ERR β inverse agonist, display a synergistic anticancer effect in pancreatic cancer.. 2022 , 19, 286-298	0
373	Cytotoxic mechanism of tioconazole involves cell cycle arrest at mitosis through inhibition of microtubule assembly.. 2022 , 74, 141-162	0
372	The natural isoflavone Biochanin-A synergizes 5-fluorouracil anticancer activity in vitro and in vivo in Ehrlich solid-phase carcinoma model.. 2022 ,	1
371	Close association between the synergistic toxicity of zearalenone-deoxynivalenol combination and microRNA221-mediated PTEN/PI3K/AKT signaling in HepG2 cells.. 2022 , 468, 153104	1
370	Pharmacological targeting of polyamine and hypusine biosynthesis reduces tumor activity of endometrial cancer.. 2022 , 1-28	1
369	Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer.. 2022 , 545, 111558	0
368	Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.. 2022 , 530, 8-8	1
367	In vitro antiviral effects of GS-441524 and itraconazole combination against feline infectious peritonitis virus.. 2022 , 144, 27-33	
366	Polystyrene nanoplastics and wastewater displayed antagonistic toxic effects due to the sorption of wastewater micropollutants.. 2022 , 819, 153063	1

365	2-Cl-IB-MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines.. 2022 , 49,	
364	Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.. 2022 ,	3
363	P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer.. 2022 , 27, 283	0
362	A Low Dose Combination of Withaferin A and Caffeic Acid Phenethyl Ester Possesses Anti-Metastatic Potential In Vitro: Molecular Targets and Mechanisms.. 2022 , 14,	2
361	ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.. 2022 , 13, 319-330	1
360	Alpha-mangostin and resveratrol, dual-drugs-loaded mucoadhesive thiolated chitosan-based nanoparticles for synergistic activity against colon cancer cells.. 2021 ,	0
359	L-Canavanine as a radiosensitization agent for human pancreatic cancer cells. 2003 , 244, 37-43	4
358	Reactive oxygen species and senescence modulatory effects of rice bran extract on 4T1 and NIH-3T3 cells co-treatment with doxorubicin. 2021 , 11, 174	1
357	EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma.. 2022 , 12, e722	0
356	A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer's Disease.. 2022 , 14, 780602	3
355	Treatment of Human Glioblastoma U251 Cells with Sulforaphane and a Peptide Nucleic Acid (PNA) Targeting miR-15b-5p: Synergistic Effects on Induction of Apoptosis.. 2022 , 27,	4
354	Inhibitory Effect of Extract and Its Active Components on Cervical Intraepithelial Neoplastic Cells.. 2022 , 27,	0
353	Hsp90 inhibition sensitizes DLBCL cells to cisplatin.. 2022 , 89, 431	1
352	Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies.. 2022 , 6, 144-155	0
351	Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.. 2022 , 13, 1048	2
350	Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ER β Positive Breast Cancer.. 2022 , 14,	0
349	A Betulinic Acid Derivative, BA5, Induces G0/G1 Cell Arrest, Apoptosis Like-Death, and Morphological Alterations in .. 2022 , 13, 846123	0
348	Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells.. 2022 ,	1

- 347 OBIF: an omics-based interaction framework to reveal molecular drivers of synergy.. **2022**, 4, lqac028 0
- 346 Cytotoxicity of Mycotoxins and Their Combinations on Different Cell Lines: A Review.. **2022**, 14, 2
- 345 Combination of second-generation proteasome inhibitor Carfilzomib with Bortezomib in four different breast cancer cell lines.. **2022**,
- 344 Inhibitory Mechanism of Combined Hydroxychavicol With Epigallocatechin-3-Gallate Against Glioma Cancer Cell Lines: A Transcriptomic Analysis.. **2022**, 13, 844199 1
- 343 Biomarkers for predicting abiraterone treatment outcome and selecting alternative therapies in castration-resistant prostate cancer.. **2022**,
- 342 Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer.. **2022**, 39, 511 1
- 341 Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation.. **2022**, 12, 835290
- 340 Combination Effect of Cilengitide with Erlotinib on TGF- β -Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells.. **2022**, 23, 1
- 339 Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects.. **2022**, 0
- 338 Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.. **2022**, 0
- 337 Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges.. **2022**, 15, 1
- 336 Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib.. **2022**, 23, 310-318 0
- 335 Combination of Ascorbic Acid and Menadione Induces Cytotoxic Autophagy in Human Glioblastoma Cells.. **2022**, 2022, 2998132 0
- 334 Combination Therapy Case Studies in Anticancer and Anti-Infectious Disease Drug Discovery and Development. **2022**, 341-384
- 333 Validation of a small molecule inhibitor of PDE6D-RAS interaction with potent anti-leukemic effects.
- 332 Canine osteosarcoma cells exhibit basal accumulation of multiple chaperone proteins and are sensitive to small molecule inhibitors of GRP78 and heat shock protein function.. **2022**, 1 1
- 331 Piperine Increases Pentagamavunone-1 Anti-cancer Activity on 4T1 Breast Cancer Through Mitotic Catastrophe Mechanism and Senescence with Sharing Targeting on Mitotic Regulatory Proteins. **2022**, 21, 0
- 330 A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile.. **2022**, 15, 0

329	Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.. 2022,	2
328	In Silico Design of a Novel Nucleotide Antiviral Agent by Free Energy Perturbation.. 2022,	
327	Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells.. 2022,	0
326	Novel Naturally Occurring Dipeptides and Single-Stranded Oligonucleotide Act as Entry Inhibitors and Exhibit a Strong Synergistic Anti-HIV-1 Profile.. 2022, 1	0
325	PI3K-mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron.. 2022, 12, e806	2
324	Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer.. 2022, 215591	0
323	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.. 2022, 51, 102268	1
322	Can insecticide mixtures be considered to surmount neonicotinoid resistance in Bemisia tabaci?. 2022, 25, 101901	0
321	Antioxidant properties of extract combination of Coccinia grandis and Blumea balsamifera: An in vitro synergistic effect. 2021, 11, 55-62	
320	Nitazoxanide and Cancer Drug Resistance: Targeting Wnt/βcatenin Signaling Pathway.. 2021,	0
319	Overcoming MDR by Associating Doxorubicin and pH-Sensitive PLGA Nanoparticles Containing a Novel Organoselenium Compound-An In Vitro Study.. 2021, 14,	2
318	Combination of cytostatic chemotherapy with cisplatin and photodynamic therapy with Radachlorin reduced resistance of K562 and Hela cell lines. 2021, 2086, 012125	
317	RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.. 2021,	1
316	HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells.. 2021, 13,	1
315	The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach.. 2021, 13,	1
314	.. 2021,	0
313	The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of and Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine.. 2021, 14,	
312	Morphological Characterization of Antibiotic Combinations.. 2021,	0

311	The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer.. 2021 , 9, 785796	0
310	Reduction of breast tumor drug resistance by 2,3,5,4'-tetrahydroxystilbene for exhibition synergic chemotherapeutic effect. 2021 , 16, e0260533	
309	Auranofin induces urothelial carcinoma cell death via reactive oxygen species production and synergy with cisplatin.. 2022 , 23, 61	2
308	Materials for Restoring Lost Activity: Old Drugs for New Bugs.. 2022 , 114302	1
307	Coexposure of Cyclopiazonic Acid with Aflatoxin B1 Involved in Disrupting Amino Acid Metabolism and Redox Homeostasis Causing Synergistic Toxic Effects in Hepatocyte Spheroids.. 2022 ,	0
306	Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.. 2022 , 17, e0266476	
305	Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects.. 2022 , 12, 64	1
304	Assessing the toxicological interaction effects of imidacloprid, thiamethoxam, and chlorpyrifos on <i>Bombus terrestris</i> based on the combination index.. 2022 , 12, 6301	0
303	Quantitative Estimation of Synergistic Toxicity of Cu and Zn on Growth of by Isobolographic Method.. 2022 , 10,	0
302	CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.. 2022 , 22, 425	0
301	SiCoDEA: a simple, fast and complete app for analyzing the effect of individual drugs and their combinations.	0
300	Metformin and Thymoquinone Synergistically Inhibit Proliferation of Imatinib-Resistant Human Leukemic Cells.. 2022 , 13, 867133	1
299	Role of the Synergistic Interactions of Environmental Pollutants in the Development of Cancer.. 2022 , 6, e2021GH000552	0
298	Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death.. 2022 , 29, 2808-2822	1
297	Presentation_1.pdf. 2020 ,	
296	Data_Sheet_1.pdf. 2020 ,	
295	Presentation_1.pdf. 2020 ,	
294	Table_1.DOCX. 2020 ,	

293 Table_2.XLSX. 2020,

292 Table_3.XLSX. 2020,

291 Table_4.XLSX. 2020,

290 Table_5.XLSX. 2020,

289 Table_6.XLSX. 2020,

288 Table_7.XLSX. 2020,

287 Image_1.JPEG. 2020,

286 Image_2.JPEG. 2020,

285 Table_1.DOCX. 2020,

284 Table_2.DOCX. 2020,

283 Table_3.DOCX. 2020,

282 Table_1.DOCX. 2019,

281 Table_1.docx. 2019,

280 Table_1.DOCX. 2019,

279 Data_Sheet_1.docx. 2018,

278 Image_1.tif. 2018,

277 Image_2.tif. 2018,

276 Table_1.xls. 2018,

275 Data_Sheet_1.PDF. **2020**,

274 Data_Sheet_1.docx. **2019**,

273 Data_Sheet_2.xlsx. **2019**,

272 Presentation_1.PPTX. **2020**,

271 Table_1.DOCX. **2020**,

270 Data_Sheet_1.PDF. **2020**,

269 DataSheet_1.pdf. **2019**,

268 Presentation1.pdf. **2018**,

267 Data_Sheet_1.docx. **2019**,

266 DataSheet_1.docx. **2020**,

265 image1.tif. **2020**,

264 image2.tif. **2020**,

263 image3.tif. **2020**,

262 image4.tif. **2020**,

261 image5.tif. **2020**,

260 image6.tif. **2020**,

259 image7.tif. **2020**,

258 Data_Sheet_1.docx. **2020**,

257 Presentation_1.PPT. **2020**,

256 Data_Sheet_1.docx. **2020**,

255 image1.jpeg. **2020**,

254 image2.jpeg. **2020**,

253 table1.pdf. **2020**,

252 DataSheet_1.pdf. **2019**,

251 Image_1.jpeg. **2019**,

250 Image_2.jpeg. **2019**,

249 An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.. **2022**, 1

248 Combination effect of doxorubicin and HIF inhibitor on MCF-7 CD44+/CD24- subpopulation cells in hypoxic condition. 58, ○

247 Colorectal Cancer. **2022**, 119-152

246 Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator. **2022**, 14, 861 1

245 Determination of deferasirox (anti-thalassemia drug) in serum and urine: cyclic voltammetry study. 5543-5557

244 Toxicity and biochemical impact of methoxyfenozide/spinetoram mixture on susceptible and methoxyfenozide-selected strains of *Spodoptera littoralis* (Lepidoptera: Noctuidae).. **2022**, 12, 6974 ○

243 Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells.. **2022**, 27, ○

242 Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.. **2022**, 10, 65 1

241 Topical nanostructured lipid carriers of alpha-mangostin and resveratrol for synergistic antioxidant activity.. **2022**,

240 Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. **2022**, 12, 651 1

239	Gambogic Acid and Piperine Synergistically Induce Apoptosis in Human Cholangiocarcinoma Cell via Caspase and Mitochondria-Mediated Pathway. 2022 , 2022, 1-12	
238	Evaluation of synergism in drug combinations and reference models for future orientations in oncology. 2022 , 100110	2
237	Synergistic Activity of Ketoconazole and Miconazole with Prochloraz in Inducing Oxidative Stress, GSH Depletion, Mitochondrial Dysfunction, and Apoptosis in Mouse Sertoli TM4 Cells. 2022 , 23, 5429	0
236	ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression. 2022 , 13,	1
235	Methotrexate and 10-hydroxycamptothecine loaded pullulan nanoparticles with the targeting property for efficient cancer therapy. 1-8	1
234	Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth.. 2022 ,	1
233	Synergistic Interaction Between Paired Combinations of Natural Antimicrobials Against Poultry-Borne Pathogens. 2022 , 13,	1
232	A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells.. 2022 , 65, 116761	0
231	In Vitro Inhibition of HIV-1 by Met-Sdf-1 Alone or in Combination with Antiretroviral Drugs. 2000 , 5, 199-204	1
230	Prevalence of Transmitted Nucleoside Analogue-Resistant HIV-1 Strains and Pre-Existing Mutations in Pol Reverse Transcriptase and Protease Region: Outcome after Treatment in Recently Infected Individuals. 2000 , 5, 7-14	21
229	Virological Response in Multidrug-Experienced HIV-1-Infected Subjects Failing Highly Active Combination Regimens after Shifting from Lamivudine to Didanosine. 2001 , 6, 41-46	4
228	Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons. 2004 , 9, 1003-1011	53
227	Synergistic Inhibition of Protease-Inhibitor-Resistant HIV type 1 by Saquinavir in Combination with Atazanavir or Lopinavir. 2007 , 12, 371-380	7
226	Key Reports from the XV International HIV Drug Resistance Workshop 2006. 2007 , 12, 131-146	1
225	The Glutaminase Inhibitor Compound 968 Exhibits Potent in vitro and in vivo Anti-tumor Effects in Endometrial Cancer.. 2022 ,	
224	Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.. 2022 , 12, 8224	1
223	Ethacrynic acid and cinnamic acid combination exhibits selective anticancer effects on K562 chronic myeloid leukemia cells.. 2022 ,	2
222	extract induces apoptosis by inhibiting the activation of AKT in SW480 human colon cancer cells.. 2022 , 60, 915-930	1

221	The Combination of a Novel GLUT1 Inhibitor and Cisplatin Synergistically Inhibits Breast Cancer Cell Growth By Enhancing the DNA Damaging Effect and Modulating the Akt/mTOR and MAPK Signaling Pathways. 2022 , 13,	1
220	Supramolecular-mediated dual-functional DNA nanocomposites for programmable cancer therapy.	
219	EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity. 2022 , 20, 854-866	1
218	Choline Kinase Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells. 2022 , 14, 1143	
217	AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation. 2022 , 106132	
216	Origanum Sipyleum Methanol Extract in Combination with Ponatinib Shows Synergistic anti-Leukemic Activities on Chronic Myeloid Leukemia Cells. 1-13	
215	JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative Neoplasm (MPN). 2022 , 106229	0
214	Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. 2022 ,	1
213	Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.	1
212	A Temporal PROTAC Cocktail-Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells. 2104823	0
211	Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. 2022 , 121608	2
210	Photodynamic Therapy : An Overview and Insights into a Prospective Mainstream Anticancer Therapy. 821-848	
209	Combination therapy of bioactive compounds with acarbose: A proposal to control hyperglycemia in type 2 diabetes.	1
208	Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer.	
207	CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. 2022 , 14, 3070	
206	Combined inhibition of KIF11 and KIF15 as an effective therapeutic strategy for gastric cancer. 2022 , 22,	0
205	Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study. 2022 , 12,	0
204	Implication of methylselenocysteine in combination chemotherapy with gemcitabine for improved anticancer efficacy. 2022 , 106238	0

- 203 Chlorogenic acid improves anti-lipogenic activity of metformin by positive regulating of AMPK signaling in HepG2 cells. 0
- 202 Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants. 0
- 201 WEE1 Inhibition Augments CDC7 (DDK) Inhibitor-Induced Cell Death in Ewing Sarcoma by Forcing Premature Mitotic Entry and Mitotic Catastrophe. **2022**, 2, 471-482
- 200 Modeling synergistic effects by using general Hill-type response surfaces describing drug interactions. **2022**, 12,
- 199 Raddeanin A synergistically enhances the anti-tumor effect of MAP30 in multiple ways, more than promoting endosomal escape. **2022**, 449, 116139
- 198 First eco-toxicological evidence of ivabradine effect on the marine bacterium *Vibrio fischeri*: A chiral view. **2022**, 838, 156617 1
- 197 Anionic dinitrosyl iron complexes behave as nitric oxide donors with selective toxicity to human glioblastoma cells. **2022**, 1266, 133506
- 196 Advantages of combined photodynamic therapy in the treatment of oncological diseases. 1
- 195 Synergistic effects of BAY606583 on docetaxel in esophageal cancer through modulation of ERK1/2.
- 194 SiCoDEA: A Simple, Fast and Complete App for Analyzing the Effect of Individual Drugs and Their Combinations. **2022**, 12, 904 1
- 193 The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK. **2022**, 20, 418 1
- 192 Two plus One: Combination Therapy Tri-systems Involving Two Membrane-Disrupting Antimicrobial Macromolecules and Antibiotics. 0
- 191 High-throughput screening identifies stevioside as a potent agent to induce apoptosis in bladder cancer cells. **2022**, 115166 0
- 190 Attenuation of SARS-CoV -2 replication and associated inflammation by concomitant targeting of viral and host cap 2'-O-ribose methyltransferases. 3
- 189 Morindone from *Morinda citrifolia* as a potential antiproliferative agent against colorectal cancer cell lines. **2022**, 17, e0270970 0
- 188 Bioinformatics Analysis Reveals FOXM1/BUB1B Signaling Pathway as a Key Target of Neosetophomone B in Human Leukemic Cells: A Gene Network-Based Microarray Analysis. 12,
- 187 Theoretical investigation of some 1,2,4-triazole-based molecules synthesized. **2022**, 0
- 186 Co-delivery of Cisplatin and Chlorin e6 by Poly(phosphotyrosine) for Synergistic Chemotherapy and Photodynamic Therapy. 0

185	BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. 2022 , 12,	2
184	5-Demethylnobiletin Inhibits Cell Proliferation, Downregulates ID1 Expression, Modulates the NF- κ B/TNF- α Pathway and Exerts Antileukemic Effects in AML Cells. 2022 , 23, 7392	0
183	Behavioral disturbances induced by cyanobacterial oligopeptides microginin-FR1, anabaenopeptin-A and microcystin-LR are associated with neuromotoric and cytotoxic changes in <i>Brachionus calyciflorus</i> . 2022 , 438, 129472	1
182	Combined toxicity of acetochlor and metribuzin on earthworm <i>Eisenia fetida</i> : Survival, oxidative stress responses and joint effect. 2022 , 178, 104583	
181	Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor. 2005 , 11, 1268-1276	11
180	Peroxisome proliferator-activated receptor β and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. 2004 , 3, 1249-1262	25
179	Caspase-mediated apoptosis and caspase-independent cell death induced by irifolven in prostate cancer cells. 2004 , 3, 1385-1396	15
178	The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. 2004 , 3, 1513-1524	16
177	Targeting ESR1 mutation-Induced transcriptional addiction in breast cancer with BET inhibition.	0
176	Development of a first-in-class unimolecular dual GIP/GLP-2 analogue, GL-0001, for the treatment of bone fragility.	
175	Synergistic Protective Effect of <i>Agastache rugosa</i> and <i>Centella asiatica</i> against UVB-Induced Damage in Human Skin Fibroblasts. 2022 , 51, 671-678	
174	Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches. 2022 , 14, 3726	
173	CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. 2022 , 12,	
172	Augmented Therapeutic Potential of EC-Synthetic Retinoids in Caco-2 Cancer Cells Using an In Vitro Approach. 2022 , 23, 9442	
171	Chrysin sensitizes osteosarcoma cells against TRAIL-induced apoptosis.	
170	Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.	
169	Robust and Efficient Assessment of Potency (REAP) as a quantitative tool for dose-response curve estimation. 11,	0
168	Are the Newer Carbapenems of Any Value against Tuberculosis. 2022 , 11, 1070	

- 167 Combination effect of cilengitide derivatives with gefitinib on TGF- β -induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells.
- 166 Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma. **2022**, 200244
- 165 Ex vivo drug testing in an ultra-rare sarcoma reveals therapeutic vulnerability and resistance.
- 164 Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells. **2022**, 14, 4027
- 163 Drug Combination Modeling: Methods and Applications in Drug Development.
- 162 High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer.
- 161 The binary combined toxicity of lithium, lead, and manganese on the proliferation of murine neural stem cells using two different models.
- 160 Combined Treatment of Bronchial Epithelial Calu-3 Cells with Peptide Nucleic Acids Targeting miR-145-5p and miR-101-3p: Synergistic Enhancement of the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene. **2022**, 23, 9348 1
- 159 Joint Action of Herbicides on Weeds and Their Risk Assessment on Earthworm (*Eisenia fetida* L.).
- 158 Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation. **2022**, 26, 330-346
- 157 The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma. **2022**, 26, 387-398 0
- 156 Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma. **2022**, 154, 113602 0
- 155 Vitamin D3 and Salinomycin synergy in MCF-7 cells cause cell death via endoplasmic reticulum stress in monolayer and 3D cell culture. **2022**, 452, 116178 1
- 154 Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma. **2022**, 14, 4535 0
- 153 Substituted boron subphthalocyanines [Prospective compounds for theranostics: Synthesis, photochemical properties and in vitro cytotoxicity. **2022**, 207, 110690 0
- 152 Measuring Herb-Drug Interaction and Synergy. **2022**, 5-14 0
- 151 Evaluation of Joint Toxicity of Btex Mixtures Using Sulfur-Oxidizing Bacteria. 0
- 150 Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment. **2022**, 20, 0

- 149 Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo. 12, 0
- 148 Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with Doxorubicin. **2022**, 23, 9903 1
- 147 Evaluating a therapeutic window for precision medicine by integrating genomic profiles and p53 network dynamics. **2022**, 5, 1
- 146 Augmented Antitumor Effect of Unripe *Rubus coreanus* Miquel Combined with Oxaliplatin in a Humanized PD-1/PD-L1 Knock-In Colorectal Cancer Mouse Model. **2022**, 11, 2876 0
- 145 Ricolinostat suppresses proliferation, promotes apoptosis, and enhances the antiproliferative activity of topoisomerase inhibitors in cervical cancer cells. 0
- 144 Folate receptor targeted nanoparticles containing niraparib and doxorubicin for treatment of high grade serous ovarian cancer. 0
- 143 Extracts of *Rheum palmatum* and *Aloe vera* Show Beneficial Properties for the Synergistic Improvement of Oral Wound Healing. **2022**, 14, 2060 0
- 142 Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development. **2022**, 12, 0
- 141 Bazı Sentezlenen 1,3-arilamino-5-[2-(substitü 1-imidazolil) etil]-1,2,4-triazol Tıvlerin Teorik İncelenmesi. 0
- 140 SIN3-HDAC complex-associated factor, a chromatin remodelling gene located in the 12p amplicon, is a potential germ cell tumour-specific oncogene. 0
- 139 Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors. **2022**, 12, 1503 2
- 138 Sustained Aurora kinase B expression confers resistance to PI3K inhibition in head and neck squamous carcinoma. 0
- 137 Combinatorial treatments of tamoxifen and SM6Met, an extract from *Cyclopia subternata* Vogel, are superior to either treatment alone in MCF-7 cells. 13, 0
- 136 Chemically Modified Bovine β -Lactoglobulin as a Broad-Spectrum Influenza Virus Entry Inhibitor with the Potential to Combat Influenza Outbreaks. **2022**, 14, 2055 0
- 135 Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity. **2022**, 65, 12200-12218 1
- 134 Overview of Nanoparticle-Based Approaches for the Combination of Photodynamic Therapy (PDT) and Chemotherapy at the Preclinical Stage. **2022**, 14, 4462 1
- 133 Amaryllidaceae-Type Alkaloids from *Pancratium maritimum*: Apoptosis-Inducing Effect and Cell Cycle Arrest on Triple-Negative Breast Cancer Cells. **2022**, 27, 5759 1
- 132 The Effect of Short-Chain Fatty Acids on Growth of *Cryptosporidium parvum* In Vitro. **2022**, 10, 1822 1

- 131 Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. **2022**, 90, 345-356 ○
- 130 Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells. **2022**, 14, 4626 1
- 129 KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45 β Pathway. 12, ○
- 128 Folate receptor targeted nanoparticles containing niraparib and doxorubicin for treatment of high grade serous ovarian cancer. ○
- 127 Cumulative Risk Meets Inter-Individual Variability: Probabilistic Concentration Addition of Complex Mixture Exposures in a Population-Based Human In Vitro Model. **2022**, 10, 549 ○
- 126 An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. **2022**, 13, ○
- 125 Quantitative Framework for Bench-to-Bedside Cancer Research. **2022**, 14, 5254 ○
- 124 Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer. **2022**, 13, ○
- 123 Structure-Based Discovery and Characterization of a Preclinical Drug Candidate for the Treatment of HIV-1 Infection. **2022**, 14, 2390 ○
- 122 Frankincense oil-loaded nanoemulsion formulation of paclitaxel and erucin: A synergistic combination for ameliorating drug resistance in breast cancer: In vitro and in vivo study. 13, ○
- 121 Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation. ○
- 120 Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinoma. ○
- 119 Design, Synthesis, and Preclinical Activity in Ovarian Cancer Models of New Phosphane-gold(I)-N-heterocyclic Carbene Complexes. ○
- 118 Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer.. ○
- 117 Combination of carboplatin and photodynamic therapy with 9-hydroxypheophorbide ? enhances mitochondrial and endoplasmic reticulum apoptotic effect in AMC-HN-3 laryngeal cancer cells. **2022**, 103135 ○
- 116 FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures. **2022**, 24, ○
- 115 Rational Engineering of a Sub-Picomolar HIV-1 Blocker. **2022**, 14, 2415 ○
- 114 Enhancing HIV-1 neutralization by increasing the local concentration of MPER-directed bnAbs. ○

113	Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis. 2022 , 13,	0
112	Targeting the ALK/MDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. 2022 , 3, 1211-1227	0
111	Discovery of a 2'-Fluoro,2'-Bromouridine Phosphoramidate Prodrug Exhibiting Anti-Yellow Fever Virus Activity in Culture and in Mice. 2022 , 10, 2098	0
110	Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma. 12,	0
109	Identification of the ultrahigh-risk subgroup in neuroblastoma cases through DNA methylation analysis and its treatment exploiting cancer metabolism.	0
108	A Quantitative Study of the Impact of Organizational Culture, Communication Management, and Clarity in Project Scope on Constructions[Project Success with Moderating Role of Project Manager] Competencies to Enhance Constructions Management Practices. 2022 , 12, 1856	0
107	The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines. 2022 , 23, 13398	1
106	PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib.	0
105	AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models. 2022 , 156, 113942	0
104	Evaluation of joint toxicity of BTEX mixtures using sulfur-oxidizing bacteria. 2023 , 325, 116435	2
103	Non-additive mixture effects of benzo[a]pyrene and pesticides in vitro and in vivo: Role of AhR signaling. 2023 , 316, 120510	0
102	Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression. 12,	0
101	BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. 2022 , 8,	1
100	A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models.	0
99	Cross-reactivity between histone demethylase inhibitor valproic acid and DNA methylation in glioblastoma cell lines. 12,	1
98	Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer. Volume 17, 5353-5374	0
97	High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients. 2022 , 23, 14300	1
96	Anti-leukemic properties of the kinase inhibitor OTSSP167 in T cell acute lymphoblastic leukemia.	0

- 95 Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action. **2023**, 209, 105485 ○
- 94 Etoposide in combination with erastin synergistically altered iron homeostasis and induced ferroptotic cell death through regulating IREB2/FPN1 expression in estrogen receptor positive-breast cancer cells. **2023**, 312, 121222 ○
- 93 Cytotoxicities of Co-occurring alternariol, alternariol monomethyl ether and tenuazonic acid on human gastric epithelial cells. **2023**, 171, 113524 ○
- 92 Design, synthesis, and biological evaluation of new arjunolic acid derivatives as anticancer agents. ○
- 91 Fabrication and characterization of bee pollen extract nanoparticles: Their potential in combination therapy against human A549 lung cancer cells. **2023**, 3, 100110 ○
- 90 Drug Combination Studies of the Dipeptide Nitrile CD24 with Curcumin: A New Strategy to Synergistically Inhibit Rhodesain of *Trypanosoma brucei rhodesiense*. **2022**, 23, 14470 ○
- 89 CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells. **2022**, 14, 5925 ○
- 88 Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer. **2022**, 14, 5894 ○
- 87 New Nanosized Systems Doxorubicin-Amphiphilic Copolymers of N-Vinylpyrrolidone and (Di)methacrylates with Antitumor Activity. **2022**, 14, 2572 1
- 86 A competition smFRET assay to study ligand-induced conformational changes of the dengue virus protease. **2023**, 32, ○
- 85 High-throughput Approaches to Uncover Synergistic Drug Combinations in Leukemia. ○
- 84 Combination Treatment of Withalongolide a Triacetate with Cisplatin Induces Apoptosis by Targeting Translational Initiation, Migration, and Epithelial to Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. **2022**, 14, 5398 ○
- 83 Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway. 10, ○
- 82 Metabolic enzyme LDHA activates Rac1 GTPase as a noncanonical mechanism to promote cancer. **2022**, 4, 1830-1846 1
- 81 Structure-Based Drug Design and Synthesis of Novel N-Aryl-2,4-bithiazole-2-amine CYP1B1-Selective Inhibitors in Overcoming Taxol Resistance in A549 Cells. **2022**, 65, 16451-16480 ○
- 80 Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies. 13, ○
- 79 Enhancement of the therapeutic efficacy of the MAP regimen using thiamine pyrophosphate-decorated albumin nanoclusters in osteosarcoma treatment. ○
- 78 Dalpiciclib Partially Abrogates ER Signaling Activation Induced by Pyrotinib In HER2+HR+Breast Cancer. ○

- 77 Inhibition of glycogen synthase kinase-3-beta (GSK3 β) blocks nucleocapsid phosphorylation and SARS-CoV-2 replication. **2022**, 3, 0
- 76 Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies. 0
- 75 Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis. **2023**, 24, 1635 1
- 74 Berberine exhibits antitumor effects by activating autophagy and apoptosis in anaplastic thyroid carcinoma cells by regulating ROS and the PI3K/AKT/mTOR signaling pathways. 0
- 73 Nanoparticles of N-Vinylpyrrolidone Amphiphilic Copolymers and Pheophorbide a as Promising Photosensitizers for Photodynamic Therapy: Design, Properties and In Vitro Phototoxic Activity. **2023**, 15, 273 1
- 72 Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. **2023**, 21, 1
- 71 Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer. 12, 0
- 70 Sequential targeting of retinoblastoma and DNA synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real-time. 0
- 69 Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. **2023**, 9, 0
- 68 Compound combinations targeting longevity: challenges and perspectives. **2023**, 101851 0
- 67 Synergistic Combination of Luteolin and Asiatic Acid on Cervical Cancer In Vitro and In Vivo. **2023**, 15, 548 0
- 66 Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Non-small-Cell Lung Cancer. **2023**, 66, 1027-1047 0
- 65 The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells. **2023**, 23, 0
- 64 Synergistic effects of concurrent photodynamic therapy with indocyanine green and chemotherapy in hepatocellular carcinoma cell lines and mouse models. **2023**, 239, 112642 0
- 63 Environmental concentrations of antifouling biocides affect cell proliferation, possibly by a synergic interaction. **2023**, 191, 102330 0
- 62 Hsp27, Hsp60, Hsp70, or Hsp90 depletion enhances the antitumor effects of resveratrol via oxidative and ER stress response in human glioblastoma cells. **2023**, 208, 115409 0
- 61 Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity. **2023**, 8, 976-986 1
- 60 Estrogen Receptor-positive Breast Cancer Cells are Sensitized by Piperine to Chemo/Radio Therapy through Lowering the expression of a NHEJ repair protein DNA-PK. 0

- 59 4-methylthiobutyl isothiocyanate synergize the antiproliferative and pro-apoptotic effects of paclitaxel in human breast cancer cells. 1-25 ○
- 58 Delphinidin-3-rutinoside from Blackcurrant Berries (*Ribes nigrum*): In Vitro Antiproliferative Activity and Interactions with Other Phenolic Compounds. **2023**, 28, 1286 ○
- 57 Synergistic Effects of Sorghum Extract and Metformin on Anti-Diabetic Activities in HepG2 Cells. **2023**, 52, 17-25 ○
- 56 Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma. **2023**, 15, 886 ○
- 55 eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. **2023**, 24, 2055 ○
- 54 Preparation and characterization of cetuximab-loaded egg serum albumin nanoparticles and their uses as a drug delivery system against Caco-2 colon cancer cells. **2023**, 14, 1 ○
- 53 Synergy of ruthenium metallo-intercalator, [Ru(dppz)₂(PIP)]²⁺, with PARP inhibitor Olaparib in non-small cell lung cancer cells. **2023**, 13, ○
- 52 Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective. **2023**, 13, ○
- 51 Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells. **2023**, 15, 91-100 ○
- 50 Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways. **2023**, 24, 3418 ○
- 49 Restricting genomic actions of innate immune mediators on fetal hematopoietic progenitor cells. **2023**, 26, 106297 ○
- 48 Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. **2023**, 24, 6998 ○
- 47 Joint effects of gamma radiation and zinc on duckweed *Lemna minor* L.. **2023**, 257, 106438 ○
- 46 Synergistic antiviral activity against drug-resistant HIV-1 by naturally occurring dipeptide and A single-stranded oligonucleotide. **2023**, 68, 100955 ○
- 45 Reduced synergistic efficacy of piperonyl butoxide in combination with alpha-cypermethrin in vitro in an insecticide-resistant strain of the sheep blowfly, *Lucilia cuprina*. **2023**, 317, 109917 ○
- 44 Disulfiram enhances cisplatin cytotoxicity by forming a novel platinum chelate Pt(DDTC)₃⁺. **2023**, 211, 115498 ○
- 43 Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. **2023**, 948, 175703 ○
- 42 Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects. ○

- 41 Quantitative analysis of effects of salvianic acid a combined with hydroxy safflower yellow a on rat endothelial cells after hypoxic injury using the combination index method. 58, ○
- 40 Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. **2023**, 556, 216063 ○
- 39 Synergistic Inhibiting Effect of Phytochemicals in Rheum palmatum on Tyrosinase Based on Metabolomics and Isobologram Analyses. **2023**, 28, 944 ○
- 38 The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics. **2023**, 424, 113503 ○
- 37 AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells. **2023**, 49, ○
- 36 Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition. **2023**, 15, 1044 ○
- 35 Dual-targeting therapy against HER3 / MET in human colorectal cancers. ○
- 34 Peptide-mediated Aqueous Synthesis of NIR-II Emitting Ag₂S Quantum Dots for Rapid Photocatalytic Bacteria Disinfection. **2023**, 135, ○
- 33 Peptide-mediated Aqueous Synthesis of NIR-II Emitting Ag₂S Quantum Dots for Rapid Photocatalytic Bacteria Disinfection. **2023**, 62, ○
- 32 Plumbagin Enhances the Anticancer Effects of PF Chemotherapy via Downregulation of the PI3K/AKT/mTOR/p70S6K Pathway in Human Tongue Squamous Cell Carcinoma. **2023**, 2023, 1-16 1
- 31 Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma. **2023**, 16, 294 ○
- 30 Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer's disease. **2023**, 355, 604-621 ○
- 29 Association of polar fraction of Ageratum conyzoides from the Brazilian Amazon with doxycycline against infection of macrophages with Ehrlichia canis. **2023**, 155, 90-97 ○
- 28 Photochemical Internalization Using Natural Anticancer Drugs, Antimetabolites, and Nanoformulations: A Systematic Study against Breast and Pancreatic Cancer Cell Lines. **2023**, 20, 1818-1841 ○
- 27 Cytotoxic and chemomodulatory effects of Phyllanthus niruri in MCF-7 and MCF-7ADR breast cancer cells. **2023**, 13, ○
- 26 Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity. **2023**, 12, 687 ○
- 25 SİNERJİSTİK İLAÇ KOMBİNASYONLARININ ANALİZİNDE GÜÇLÜ MATEMATİKSEL VE İSTATİSTİKSEL YAKLAŞIMLAR. **2023**, 47, 2-2 ○
- 24 Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer. **2023**, 13, ○

23	Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia. 2023 , 12,	1
22	Development of a First-in-Class Unimolecular Dual GIP / GLP -2 Analogue, GL -0001, for the Treatment of Bone Fragility.	0
21	Anti-Inflammatory, Antioxidant Activities, and Phytochemical Characterization of Edible Plants Exerting Synergistic Effects in Human Gastric Epithelial Cells. 2023 , 12, 591	0
20	Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides. 2023 , 212, 105571	0
19	Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2. 2023 , 8,	0
18	mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer. 2023 , 8,	0
17	Combined inhibition of polyamine metabolism and eIF5A hypusination suppresses colorectal cancer growth through a converging effect on MYC translation. 2023 , 559, 216120	0
16	Evaluating the RIST Molecular-Targeted Regimen in a Three-Dimensional Neuroblastoma Spheroid Cell Culture Model. 2023 , 15, 1749	0
15	Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in Anticancer Adjuvant Cisplatin Therapy. 2023 , 24, 5715	0
14	Eugenol-loaded mesoporous silica nanoparticles enhance the sensitivity of cisplatin against AGS human gastric adenocarcinoma cell line. 2023 , 25,	0
13	Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner.	0
12	Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice. 2023 , 13,	0
11	Technetium-99m labeled core shell hyaluronate nanoparticles as tumor responsive, metastatic skeletal lesion targeted combinatorial theranostics. 2023 , 312, 120840	0
10	Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.	0
9	Paris polyphylla Sm. Induces Reactive Oxygen Species and Caspase 3-Mediated Apoptosis in Colorectal Cancer Cells In Vitro and Potentiates the Therapeutic Significance of Fluorouracil and Cisplatin. 2023 , 12, 1446	0
8	High Throughput Fluorescence-Based In Vitro Experimental Platform for the Identification of Effective Therapies to Overcome Tumour Microenvironment-Mediated Drug Resistance in AML. 2023 , 15, 1988	0
7	Prognostic Relevance and In Vitro Targeting of Concomitant PTEN and p16 Deficiency in Chordomas. 2023 , 15, 1977	0
6	Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals. 2023 , 67,	0

- 5 Concurrent treatment of flavonol with chemotherapeutics potentiates or counteracts the therapeutic implications in cervical cancer cells. **2023**, 35, ○
- 4 Evaluating preclinical evidence for clinical translation in childhood brain tumours: Guidelines from the CONNECT, PNOC, and ITCC brain networks. 13, ○
- 3 Lethal and repellent effect of amitraz, eugenol and thymol against *Triatoma infestans*, the main vector of *Trypanosoma cruzi* in the southern of America. ○
- 2 Growth and invasion inhibition of T47D ductal carcinoma cells by the association of docetaxel with a bioactive agent in neutral nanosuspension. **2023**, 13, 145-157 ○
- 1 DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer. **2023**, 1866, 194939 ○